lactic acid and Benign Neoplasms studies

Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed)
2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.

Research Excerpts

Excerpt	Relevance	Reference
"Hand-foot syndrome (HFS) is a dose-limiting toxicity of capecitabine for which no effective preventative treatment has been definitively demonstrated."	9.14	Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5. ( Berenberg, JL; Christian, D; Delaune, R; Loprinzi, CL; Menon, SP; Pajon, ER; Qin, R; Rowland, KM; Satele, DV; Thomas, S; Wolf, SL, 2010)
"Lactic acidosis characterizes the tumor microenvironment (TME) and is involved in the mechanisms leading to cancer progression and dissemination through the reprogramming of tumor and local host cells (e."	8.31	Extracellular Lactic Acidosis of the Tumor Microenvironment Drives Adipocyte-to-Myofibroblast Transition Fueling the Generation of Cancer-Associated Fibroblasts. ( Andreucci, E; Biagioni, A; Calorini, L; Fioretto, BS; Manetti, M; Matucci-Cerinic, M; Romano, E; Rosa, I, 2023)
" Our previous works suggested that cancer cells reverted to OXPHOS, when they were exposed to lactic acidosis, a common factor in tumor environment."	7.83	Lactic acidosis switches cancer cells from aerobic glycolysis back to dominant oxidative phosphorylation. ( Hu, X; Wu, H; Ying, M, 2016)
" We propose the research and development of therapeutic approaches for preemptive, short- and long-term management of cancer pain using available drugs or nutraceutical agents that can suppress or neutralize lactic acid production in combination with formaldehyde scavengers."	7.81	Acidosis and Formaldehyde Secretion as a Possible Pathway of Cancer Pain and Options for Improved Cancer Pain Control. ( Fang, JY; Han, B; Hoang, BX; Nimni, M; Shaw, DG, 2015)
"Lactic acidosis is common to most solid tumors and has been found to affect infiltrating immune cells."	7.78	Tumor lactic acidosis suppresses CTL function by inhibition of p38 and JNK/c-Jun activation. ( Gottfried, E; Hu, B; Kreutz, M; Mendler, AN; Noessner, E; Prinz, PU, 2012)
"Like the tumors, the blastocysts, placenta, trophoblasts and decidual immune cells can also produce a large amount of lactic acid through aerobic glycolysis during the early pregnancy."	6.66	Lactic Acid: A Novel Signaling Molecule in Early Pregnancy? ( Huang, XB; Liao, AH; Ma, LN; Mor, G; Muyayalo, KP, 2020)
"Hand-foot syndrome (HFS) is a dose-limiting toxicity of capecitabine for which no effective preventative treatment has been definitively demonstrated."	5.14	Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5. ( Berenberg, JL; Christian, D; Delaune, R; Loprinzi, CL; Menon, SP; Pajon, ER; Qin, R; Rowland, KM; Satele, DV; Thomas, S; Wolf, SL, 2010)
" MCT4 is associated with the export of lactic acid from cancer cells under hypoxia, so inhibition of MCT4 may lead to cytotoxic levels of intracellular lactate."	4.31	Discovery of Clinical Candidate AZD0095, a Selective Inhibitor of Monocarboxylate Transporter 4 (MCT4) for Oncology. ( Beattie, D; Buttar, D; Clark, R; Cook, CR; Critchlow, SE; Goldberg, FW; Hopcroft, L; Hughes, G; Kavanagh, SL; Kawatkar, A; Kettle, JG; Komen, JC; Lamont, GM; McGuire, TM; Morentin Gutierrez, P; Ting, AKT, 2023)
"Lactic acidosis characterizes the tumor microenvironment (TME) and is involved in the mechanisms leading to cancer progression and dissemination through the reprogramming of tumor and local host cells (e."	4.31	Extracellular Lactic Acidosis of the Tumor Microenvironment Drives Adipocyte-to-Myofibroblast Transition Fueling the Generation of Cancer-Associated Fibroblasts. ( Andreucci, E; Biagioni, A; Calorini, L; Fioretto, BS; Manetti, M; Matucci-Cerinic, M; Romano, E; Rosa, I, 2023)
" Lactic acidosis correlates with cancer malignancy, and the benefit it offers to tumours has been the subject of numerous hypotheses."	4.31	Warburg-associated acidification represses lactic fermentation independently of lactate, contribution from real-time NMR on cell-free systems. ( Bendridi, N; Berger, MA; Brunet, L; Daverio, Z; Kolkman, M; Panthu, B; Perrier, J; Rautureau, GJP; Sanglar, C, 2023)
" c-MYC also regulates glutamine metabolism and drives progression of asymptomatic precursor plasma cell (PC) malignancies to symptomatic multiple myeloma (MM)."	3.88	Glutamine-derived 2-hydroxyglutarate is associated with disease progression in plasma cell malignancies. ( Dutta, T; Ghosh, T; Gonsalves, WI; Hitosugi, T; Jevremovic, D; Kumar, SK; Nair, KS; Petterson, XM; Ramakrishnan, V; Sakrikar, D; Wellik, L, 2018)
" Our previous works suggested that cancer cells reverted to OXPHOS, when they were exposed to lactic acidosis, a common factor in tumor environment."	3.83	Lactic acidosis switches cancer cells from aerobic glycolysis back to dominant oxidative phosphorylation. ( Hu, X; Wu, H; Ying, M, 2016)
" We propose the research and development of therapeutic approaches for preemptive, short- and long-term management of cancer pain using available drugs or nutraceutical agents that can suppress or neutralize lactic acid production in combination with formaldehyde scavengers."	3.81	Acidosis and Formaldehyde Secretion as a Possible Pathway of Cancer Pain and Options for Improved Cancer Pain Control. ( Fang, JY; Han, B; Hoang, BX; Nimni, M; Shaw, DG, 2015)
" When cancer cells are under regular culture condition, they show Warburg effect; whereas under lactic acidosis, they show a nonglycolytic phenotype, characterized by a high ratio of oxygen consumption rate over glycolytic rate, negligible lactate production and efficient incorporation of glucose carbon(s) into cellular mass."	3.80	Beyond Warburg effect--dual metabolic nature of cancer cells. ( Dai, C; Ding, Z; Hu, D; Hu, X; Ji, B; Luo, Y; Pan, Q; Wu, H; Xie, J, 2014)
"Lactic acidosis is common to most solid tumors and has been found to affect infiltrating immune cells."	3.78	Tumor lactic acidosis suppresses CTL function by inhibition of p38 and JNK/c-Jun activation. ( Gottfried, E; Hu, B; Kreutz, M; Mendler, AN; Noessner, E; Prinz, PU, 2012)
" In GS-2 glioblastoma cells, PI3K inhibition by LY294002 or everolimus caused hyperpolarized lactate to drop to 42 +/- 12% and to 76 +/- 5%, respectively."	3.76	Noninvasive detection of target modulation following phosphatidylinositol 3-kinase inhibition using hyperpolarized 13C magnetic resonance spectroscopy. ( Brandes, AH; Chaumeil, MM; Dafni, H; Haas-Kogan, DA; James, CD; Kurhanewicz, J; Nelson, SJ; Ronen, SM; Sukumar, S; Vancriekinge, M; Venkatesh, HS; Vigneron, DB; Ward, CS, 2010)
"Lactate in tumors has long been considered "metabolic junk" derived from the glycolysis of cancer cells and utilized only as a biomarker of malignancy, but is presently believed to be a pivotal regulator of tumor development, maintenance and metastasis."	3.01	Engineering lactate-modulating nanomedicines for cancer therapy. ( Chen, J; Shi, J; Wu, C; Zhu, Y, 2023)
"As a result of metabolic reprogramming, cancer cells display high rates of glycolysis, causing an excess production of lactate along with an increase in extracellular acidity."	3.01	Targeting monocarboxylate transporters (MCTs) in cancer: How close are we to the clinics? ( Afonso, J; Baltazar, F; Gupta, R; Kumar, V; Rani, R; Sharma, D; Singh, M, 2023)
"A long-standing question in cancer biology has been why oxygenated tumors ferment the majority of glucose they consume to lactate rather than oxidizing it in their mitochondria, a phenomenon known as the 'Warburg effect."	3.01	The Warburg effect: a signature of mitochondrial overload. ( Patti, GJ; Wang, Y, 2023)
"Owing to its connection to cancer metabolism, lactate is a compound that has been a focus of interest in field of cancer biochemistry for more than a century."	3.01	Lactate in exhaled breath condensate and its correlation to cancer: challenges, promises and a call for data. ( Kalapos, MP; Ruzsányi, V, 2023)
"Lactate acidosis is often observed in the tumor microenvironment (TME) of solid tumors."	3.01	Lactate acidosis and simultaneous recruitment of TGF-β leads to alter plasticity of hypoxic cancer cells in tumor microenvironment. ( Arora, MK; Banerjee, S; Kaithwas, G; Mishra, SS; Rastogi, S; Ravichandiran, V; Roy, S; Singh, L, 2023)
"One of the defining hallmarks of cancer cells is their ability to reprogram their metabolism to suit their needs."	2.82	Metabolic reservoir cycles in cancer. ( Le, A; Quinones, A; Zhang, C, 2022)
"Lactic acid is a "metabolic waste" product of glycolysis that is produced in the body."	2.82	Tumor Microenvironment: Lactic Acid Promotes Tumor Development. ( Gao, Y; Liu, G; Shang, A; Wu, J; Yuan, Y; Zhou, H, 2022)
"Tumors have long been known to rewire their metabolism to endorse their proliferation, growth, survival, and invasiveness."	2.82	Historical perspective of tumor glycolysis: A century with Otto Warburg. ( Bononi, G; Di Bussolo, V; Granchi, C; Masoni, S; Minutolo, F; Tuccinardi, T, 2022)
"Lactic acid production has been regarded as a mechanism by which malignant cells escape immunosurveillance."	2.82	Lactic acid and lactate: revisiting the physiological roles in the tumor microenvironment. ( Apostolova, P; Pearce, EL, 2022)
"Glycolysis is the backbone of cancer cell metabolism, and cancer cells have evolved various mechanisms to enhance it."	2.82	Tumor glycolysis, an essential sweet tooth of tumor cells. ( Ghosh, S; Kumar, S; Paul, S, 2022)
"Most cancer cells are characterized by an enhanced rate of tumor glycolysis to ensure the energy demand of fast-growing cancer cells leading to increased lactate production."	2.82	Role of LDH in tumor glycolysis: Regulation of LDHA by small molecules for cancer therapeutics. ( Rani, R; Sharma, D; Singh, M, 2022)
"Anorexia and cancer cachexia produce significant loss of adipose tissue and muscle mass and eventually reduce survival in cancer patients."	2.75	A phase II study of an herbal decoction that includes Astragali radix for cancer-associated anorexia in patients with advanced cancer. ( Lee, JJ, 2010)
"A characteristic feature of tumors is high production of lactic acid due to enhanced glycolysis."	2.73	Inhibitory effect of tumor cell-derived lactic acid on human T cells. ( Ammer, J; Andreesen, R; Edinger, M; Fischer, K; Gottfried, E; Hoffmann, P; Hoves, S; Krause, SW; Kreutz, M; Kunz-Schughart, L; Mackensen, A; Meidenbauer, N; Renner, K; Rothe, G; Schwarz, S; Timischl, B; Voelkl, S, 2007)
"Proliferating cancer cells have high energy demands, which is mainly obtained through glycolysis."	2.72	In Vivo Anticancer Activity of AZD3965: A Systematic Review. ( Afonso, J; Antunes, B; Baltazar, F; Batista, A; Pinto-Ribeiro, F; Silva, A, 2021)
" In this Review, we describe how the bioavailability of lactate differs in the microenvironments of tumours and inflammatory diseases compared with normal tissues, thus contributing to the establishment of specific immunological states in disease."	2.72	Lactate modulation of immune responses in inflammatory versus tumour microenvironments. ( Certo, M; Ho, PC; Mauro, C; Pucino, V; Tsai, CH, 2021)
"Metabolic changes in cancer and metastasis upregulation of glycolysis is observed in many primary and metastatic cancers and aerobic glycolysis is the most favorable mechanism for glucose metabolism in cancer cells, and it is a kind of evolutionary change."	2.72	Digging deeper through glucose metabolism and its regulators in cancer and metastasis. ( Banihashemi, S; Deris Zayeri, Z; Ghanavat, M; Kazemi, SM; Saki, N; Shahrouzian, M, 2021)
"Moreover, many metastases display different metabolic traits compared with the tumours from which they originate, enabling survival and growth in the new environment."	2.72	The metabolism of cancer cells during metastasis. ( Bergers, G; Fendt, SM, 2021)
"The preventable nature of cancer and the importance of a complex multi-level approach in anticancer therapy motivate the search for novel avenues of establishing the anticancer environment in the human body."	2.72	Postbiotics, Metabolic Signaling, and Cancer. ( Ruml, T; Vrzáčková, N; Zelenka, J, 2021)
"The Warburg effect is the preference of cancer cell for glycolysis that produces lactate even when sufficient oxygen is provided."	2.72	Protein networks linking Warburg and reverse Warburg effects to cancer cell metabolism. ( Bernstein, LH; Elberry, MH; Elmehrath, AO; Johar, D; Khalil, RM; Shalabi, SA; Zaky, S, 2021)
"route, in various types of cancer disease such as non-small cell lung cancer and advanced breast cancer."	2.67	Experimental studies and preliminary clinical trial of vinorelbine-loaded polymeric bioresorbable implants for the local treatment of solid tumors. ( Bouffard, P; Caty, A; Fournier, C; Hecquet, B; Krikorian, A; Lefebvre, JL; Merle, S; Vanseymortier, L; Vert, M; Vilain, MO, 1991)
"For energy production, cancer cells may use 4 main fuels that are shuttled in 5 different metabolic pathways."	2.66	Monocarboxylate transporters in cancer. ( Mina, E; Payen, VL; Porporato, PE; Sonveaux, P; Van Hée, VF, 2020)
"In 1920s, Warburg has claimed that cancer cells are more active in glycolysis than normal cells and use much more glucose in order to obtain more ATP for metabolic activities, then this is named as Warburg effect."	2.66	Crucial players in glycolysis: Cancer progress. ( Abbaszadeh, Z; Biray Avcı, Ç; Çeşmeli, S, 2020)
"In the autocrine pathway, cancer cell-generated lactate activates GPR81 on cancer cells; in the paracrine pathway, cancer cell-generated lactate activates GPR81 on immune cells, endothelial cells, and adipocytes present in tumor stroma."	2.66	Lactate/GPR81 signaling and proton motive force in cancer: Role in angiogenesis, immune escape, nutrition, and Warburg phenomenon. ( Brown, TP; Ganapathy, V, 2020)
"Most cancer cells display a glycolytic phenotype, with increased glucose consumption and glycolysis rates, and production of lactate as the end product, independently of oxygen concentrations."	2.66	Lactate and Lactate Transporters as Key Players in the Maintenance of the Warburg Effect. ( Afonso, J; Baltazar, F; Granja, S; Pereira-Nunes, A, 2020)
"Like the tumors, the blastocysts, placenta, trophoblasts and decidual immune cells can also produce a large amount of lactic acid through aerobic glycolysis during the early pregnancy."	2.66	Lactic Acid: A Novel Signaling Molecule in Early Pregnancy? ( Huang, XB; Liao, AH; Ma, LN; Mor, G; Muyayalo, KP, 2020)
"Metabolic reprogramming in cancer cells entails activities that involve several enzymes and metabolites to convert nutrient into building blocks that alter energy metabolism to fuel rapid cell division."	2.66	Cancer Cell Metabolites: Updates on Current Tracing Methods. ( Maniam, S, 2020)
"It is widely acknowledged that cancer cell energy metabolism relies mainly on anaerobic glycolysis; this phenomenon is described as the Warburg effect."	2.66	Revisiting the Warburg Effect: Diet-Based Strategies for Cancer Prevention. ( Gong, N; Kim, C; Kim, SH; Kong, G; Kwon, SH; Lee, H; Park, J; Tran, Q, 2020)
"In solid tumors, the microenvironment is often immunosuppressive and hypoxic regions are prevalent."	2.66	Oncometabolites lactate and succinate drive pro-angiogenic macrophage response in tumors. ( Griffioen, AW; Huijbers, EJM; Kes, MMG; Van den Bossche, J, 2020)
"Especially in solid tumors these metabolic changes significantly influence the tumor microenvironment (TME) and affect tumor infiltrating immune cells."	2.61	The Metabolic Profile of Tumor and Virally Infected Cells Shapes Their Microenvironment Counteracting T Cell Immunity. ( Magalhaes, I; Mattsson, J; Schurich, A; Yogev, O, 2019)
"Unlike cancer cells, immune cells are not subject to a "Darwinian evolutionary pressure" that would allow them to adapt to developing tumors but are often irrevocably affected to local nutrient deprivation."	2.61	Tumor Microenvironment: A Metabolic Player that Shapes the Immune Response. ( Cassim, S; Pouyssegur, J, 2019)
"Global metabolism of cancers exhibits a peculiar phenotype that is lactate acidosis (high lactate with acidic pH) in tumor microenvironment."	2.61	Lactate as a signaling molecule: Journey from dead end product of glycolysis to tumor survival. ( Chhonker, SK; Koiri, RK; Mehrotra, A; Naik, RA; Rawat, D; Trigun, SK, 2019)
"Indeed, hypoxia benefits cancer cells in their growth, survival, and metastasis."	2.61	Hypoxia/pseudohypoxia-mediated activation of hypoxia-inducible factor-1α in cancer. ( Harada, H; Hayashi, Y; Huang, G; Yokota, A, 2019)
"However, cancers evolve to evade immune detection."	2.61	Can Exercise-Induced Modulation of the Tumor Physiologic Microenvironment Improve Antitumor Immunity? ( Ashcraft, KA; Betof Warner, A; Dewhirst, MW; Nair, SK; Zhang, X, 2019)
"The extracellular milieu of tumors is generally assumed to be immunosuppressive due in part to metabolic factors."	2.61	The Tumor Metabolic Microenvironment: Lessons from Lactate. ( Chen, L; García-Cañaveras, JC; Rabinowitz, JD, 2019)
"Both cancer and Alzheimer's disease (AD) are emerging as metabolic diseases in which aberrant/dysregulated glucose metabolism and bioenergetics occur, and play a key role in disease progression."	2.61	Synthesis and metabolism of methylglyoxal, S-D-lactoylglutathione and D-lactate in cancer and Alzheimer's disease. Exploring the crossroad of eternal youth and premature aging. ( Armeni, T; Atlante, A; de Bari, L; Kalapos, MP, 2019)
"These unexplored aspects of cancer biochemistry might be exploited for therapeutic benefit."	2.58	Including the mitochondrial metabolism of L-lactate in cancer metabolic reprogramming. ( Atlante, A; de Bari, L, 2018)
"Targeting cancer metabolism for therapy has received much attention over the last decade with various small molecule inhibitors entering clinical trials."	2.58	Targeting cancer metabolism through synthetic lethality-based combinatorial treatment strategies. ( Bajpai, R; Shanmugam, M, 2018)
"Inflammation is associated with the accumulation of lactate at sites of tumor-growth and inflammation."	2.58	Lactate transporters as therapeutic targets in cancer and inflammatory diseases. ( Cucchi, D; Mauro, C; Pucino, V, 2018)
"In order to establish a pan-cancer test, biomarkers for two fundamental biophysical mechanisms have been exploited."	2.55	EDIM-TKTL1/Apo10 Blood Test: An Innate Immune System Based Liquid Biopsy for the Early Detection, Characterization and Targeted Treatment of Cancer. ( Coy, JF, 2017)
"Glucose is a key metabolite used by cancer cells to generate ATP, maintain redox state and create biomass."	2.55	Metabolic coupling and the Reverse Warburg Effect in cancer: Implications for novel biomarker and anticancer agent development. ( Curry, J; Domingo-Vidal, M; Martinez-Outschoorn, U; Philp, N; Roche, M; Tanson, K; Wilde, L, 2017)
"In this Review, we discuss how cancer cells reprogramme their metabolism and that of other cells within the tumour microenvironment in order to survive and propagate, thus driving disease progression; in particular, we highlight potential metabolic vulnerabilities that might be targeted therapeutically."	2.55	Cancer metabolism: a therapeutic perspective. ( Lisanti, MP; Martinez-Outschoorn, UE; Peiris-Pagés, M; Pestell, RG; Sotgia, F, 2017)
"We hypothesize that lactagenesis for carcinogenesis is the explanation and purpose of the Warburg Effect."	2.55	Reexamining cancer metabolism: lactate production for carcinogenesis could be the purpose and explanation of the Warburg Effect. ( Brooks, GA; San-Millán, I, 2017)
"T cell dysfunction in solid tumors results from multiple mechanisms."	2.55	Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies. ( Anderson, KG; Greenberg, PD; Stromnes, IM, 2017)
"Although interest in lactate for cancer development only appeared recently, pharmacological molecules blocking its metabolism are already in phase I/II clinical trials."	2.53	Hypoxia, cancer metabolism and the therapeutic benefit of targeting lactate/H(+) symporters. ( Marchiq, I; Pouysségur, J, 2016)
"Rather than a general switch promoting metastasis as a whole, a succession of metabolic adaptations is more likely needed to promote different steps of the metastatic process."	2.53	Metabolic changes associated with tumor metastasis, part 1: tumor pH, glycolysis and the pentose phosphate pathway. ( Baselet, B; Payen, VL; Porporato, PE; Sonveaux, P, 2016)
"It was therefore assumed that cancer cells were generating energy using glycolysis rather than mitochondrial oxidative phosphorylation, and that the mitochondria were dysfunctional."	2.53	The Warburg effect: 80 years on. ( Morten, KJ; Newport, E; Potter, M, 2016)
"Both cancer and diabetes have been associated with abnormal lactate metabolism and high level of lactate production is the key biological property of these diseases."	2.53	Lactate, a Neglected Factor for Diabetes and Cancer Interaction. ( Atefi, M; Dong, Y; Elshimali, Y; Liu, Y; Vadgama, JV; Wu, Y, 2016)
"Although anoikis is a barrier to metastasis, cancer cells have often acquired elevated threshold for anoikis and hence heightened metastatic potential."	2.52	The Warburg effect in tumor progression: mitochondrial oxidative metabolism as an anti-metastasis mechanism. ( Cai, Q; Lu, J; Tan, M, 2015)
"The nutrient demands of cancer cannot be met by normal cell metabolism."	2.52	Sirtuins and the Metabolic Hurdles in Cancer. ( German, NJ; Haigis, MC, 2015)
"Immunotherapy of cancer is a promising therapeutic approach which aims to eliminate malignancies by inducing or enhancing an immune response against the tumor."	2.52	Particulate Systems Based on Poly(Lactic-co-Glycolic)Acid (pLGA) for Immunotherapy of Cancer. ( Amidi, M; Fransen, MF; Hennink, WE; Kleinovink, JW; Ossendorp, F; Rahimian, S, 2015)
"In many solid tumors, imbalance between the demand of rapidly proliferating cancer cells and the capabilities of the vascular system generates areas with insufficient oxygen supply."	2.50	Carbonic anhydrase IX: regulation and role in cancer. ( Benej, M; Pastorek, J; Pastorekova, S, 2014)
"Interaction between cancer cells and immune system critically affects development, progression and treatment of human malignancies."	2.50	"In vitro" 3D models of tumor-immune system interaction. ( Hirt, C; Iezzi, G; Martin, I; Mele, V; Mengus, C; Muraro, MG; Papadimitropoulos, A; Spagnoli, GC; Terracciano, L, 2014)
" Their efficacy has been tested in tumor xenografted mice and considerable experimental findings have stimulated researchers to further improve the bioavailability of these nutraceuticals."	2.50	Targeting cancer with nano-bullets: curcumin, EGCG, resveratrol and quercetin on flying carpets. ( Aras, A; Farooqi, AA; Hechenleitner, AA; Khokhar, AR; Pineda, EA; Qureshi, MZ; Silva, MF; Sobczak-Kupiec, A, 2014)
"This occurs because cancer also uses glycolysis, which does not need oxygen or arteries."	2.50	ALPHA glycolytic vasculogenesis better correlates with MRI and CT imaging techniques than the traditional oxygen vasculogenesis theory. ( Haaga, JR; Haaga, R; Love, Z; Moulter, J; Patel, I, 2014)
"The common preference of cancers for lactic acid-generating metabolic energy pathways has led to proposals that their reprogrammed metabolism confers growth advantages such as decreased susceptibility to hypoxic stress."	2.49	Cancer-generated lactic acid: a regulatory, immunosuppressive metabolite? ( Choi, SY; Collins, CC; Gout, PW; Wang, Y, 2013)
"The most aggressive and invasive cancers, which are often hypoxic, rely on exacerbated glycolysis to meet the increased demand for ATP and biosynthetic precursors and also rely on robust pH-regulating systems to combat the excessive generation of lactic and carbonic acids."	2.49	Disrupting proton dynamics and energy metabolism for cancer therapy. ( Chiche, J; Parks, SK; Pouysségur, J, 2013)
"Lactate mediates cancer cell intrinsic effects on metabolism and has additional non-tumor cell autonomous effects that drive tumorigenesis."	2.49	Targeting lactate metabolism for cancer therapeutics. ( Cleveland, JL; Doherty, JR, 2013)
"Most solid tumors are known to rely on glycolysis for energy production and this activity leads to production of important amounts of lactate, which are exported into the extracellular milieu, contributing to the acidic microenvironment."	2.48	Role of monocarboxylate transporters in human cancers: state of the art. ( Azevedo-Silva, J; Baltazar, F; Casal, M; Longatto-Filho, A; Pinheiro, C; Schmitt, FC, 2012)
"Can we consider cancer to be a "metabolic disease"? Tumors are the result of a metabolic selection, forming tissues composed of heterogeneous cells that generally express an overactive metabolism as a common feature."	2.48	Anticancer agents that counteract tumor glycolysis. ( Granchi, C; Minutolo, F, 2012)
"Given its pleiotropic effects on cancer biology, PKM2 represents an attractive target for cancer therapy."	2.48	Emerging roles of PKM2 in cell metabolism and cancer progression. ( Luo, W; Semenza, GL, 2012)
"As mortality due to cancer continues to rise, advances in nanotechnology have significantly become an effective approach for achieving efficient drug targeting to tumour tissues by circumventing all the shortcomings of conventional chemotherapy."	2.47	PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. ( Acharya, S; Sahoo, SK, 2011)
"Recent study revealed that most of cancer cells form acidic environment and have many, large size acidic organelle, especially lysosomes due to cancer specific proton dynamics induced by active aerobic glycolysis without TCA cycle in the mitochondoria."	2.47	[Encounter of cancer cells with bone. Development of cancer therapy targeted on acidic microenvironment and acidic organelle of cancer cells]. ( Kusuzaki, K, 2011)
"Starting with a brief introduction to cancer nanotechnology, we then discuss developmental aspects and the in vitro and in vivo efficacy of PLGA-based nanocarriers in terms of targeted drug or gene delivery."	2.47	Engineered PLGA nanoparticles: an emerging delivery tool in cancer therapeutics. ( Das, M; Jain, AK; Jain, S; Swarnakar, NK, 2011)
" Their introduction into the clinical setting is hindered largely by their poor solubility, rapid metabolism, or a combination of both, ultimately resulting in poor bioavailability upon oral administration."	2.47	Advanced drug delivery systems of curcumin for cancer chemoprevention. ( Aqil, F; Bansal, SS; Goel, M; Gupta, RC; Vadhanam, MV, 2011)
"Development of safe and effective cancer vaccine formulation is a primary focus in the field of cancer immunotherapy."	2.47	Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations. ( Haddadi, A; Hamdy, S; Hung, RW; Lavasanifar, A, 2011)
"Metastasis of tumors is promoted by lactate-induced secretion of hyaluronan by tumor-associated fibroblasts that create a milieu favorable for migration."	2.47	Lactate: a metabolic key player in cancer. ( Hirschhaeuser, F; Mueller-Klieser, W; Sattler, UG, 2011)
"Accumulation of lactate within tumors has been correlated with poor clinical outcomes."	2.46	Tumor metabolism of lactate: the influence and therapeutic potential for MCT and CD147 regulation. ( Dewhirst, MW; Kennedy, KM, 2010)
"Since enhanced glycolysis in cancer is associated with lactate production, tumor cells must find a way to eliminate lactic acid to prevent cellular acidification."	2.45	Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. ( Ganapathy, V; Prasad, PD; Thangaraju, M, 2009)
"One of the main challenges of anti-cancer therapy is to specifically target these drugs to malignant cells."	2.45	Tumor cell energy metabolism and its common features with yeast metabolism. ( Devin, A; Diaz-Ruiz, R; Rigoulet, M; Uribe-Carvajal, S, 2009)
"This distinctive metabolic nature of cancer cells is already being exploited as a diagnostic tool but is yet to be harnessed as a therapeutic intervention."	2.44	Hypoxia signalling controls metabolic demand. ( Brahimi-Horn, MC; Chiche, J; Pouysségur, J, 2007)
"DC have been shown to infiltrate many tumors but both, circulating and tumor-infiltrating DC from cancer patients, appear to be phenotypically and functionally defective."	2.44	Tumor-induced modulation of dendritic cell function. ( Gottfried, E; Kreutz, M; Mackensen, A, 2008)
"Recent studies arguing that cancer cells benefit from this phenomenon, termed the Warburg effect, have renewed discussions about its exact role as cause, correlate, or facilitator of cancer."	2.43	Cancer's molecular sweet tooth and the Warburg effect. ( Dang, CV; Kim, JW, 2006)
"Low lactate tumors (8 micromol/g)."	2.42	Lactate: mirror and motor of tumor malignancy. ( Mueller-Klieser, WF; Walenta, S, 2004)
"Low lactate tumors (< median of approx."	2.42	Lactate in solid malignant tumors: potential basis of a metabolic classification in clinical oncology. ( Mueller-Klieser, W; Schroeder, T; Walenta, S, 2004)
"However, in tumors a high number of macrophages persists and might contribute to the ongoing growth, neovascularization, and metastasis of malignant cells."	2.41	Microenvironmental influence on macrophage regulation of angiogenesis in wounds and malignant tumors. ( Bishop, ET; Brown, NJ; Crowther, M; Lewis, CE, 2001)
"Although new strategies for breast cancer treatment have yielded promising results, most drugs can lead to serious side effects when applied systemically."	1.91	Effective breast cancer therapy based on palmitic acid-loaded PLGA nanoparticles. ( Cavalcante, RS; Cruz, LJ; de Araújo Júnior, RF; Eich, C; Gu, Z; He, Y; Schomann, T; Yu, Z, 2023)
"Synthetic anticancer catalysts offer potential for low-dose therapy and the targeting of biochemical pathways in novel ways."	1.91	Targeting cancer lactate metabolism with synergistic combinations of synthetic catalysts and monocarboxylate transporter inhibitors. ( Bolitho, EM; Bridgewater, HE; Coverdale, JPC; Romero-Canelón, I; Sadler, PJ, 2023)
"Lactic acid is an immunosuppressive molecule with crucial roles in tumor cells' immune escape, which could largely be attributed to its negative effects on the T cells present in the tumor microenvironment (TME)."	1.91	MicroRNA-124 Enhances T Cells Functions by Manipulating the Lactic Acid Metabolism of Tumor Cells. ( Fallah-Mehrjardi, K; Hadjati, J; Jafarzadeh, L; Javad Tavassolifar, M; Khakpoor-Koosheh, M; Masoumi, E; Mirzaei, HR; Noorbakhsh, F; Rezaei, N; Rostamian, H, 2023)
"However, IFNγ modulation for cancer therapy is still unsuccessful due to its complex effects on various host cells."	1.91	IFNγ blockade in capillary leak site improves tumour chemotherapy by inhibiting lactate-induced endocytosis of vascular endothelial-cadherins. ( Duan, X; Li, P; Lou, X; Ni, C; Qin, Z; Wan, J; Wang, L; Wang, R; Yao, X; Zhang, L, 2023)
"The general condition of patients with malignancy who have referred to the emergency department should be evaluated and it should be shown that they are not in any oncological emergency."	1.91	Prognostic Importance of Lactate and Blood Gas Parameters in Predicting Mortality in Patients with Critical Malignancies. ( Ak, E; Avci, A; Can, D; Erdur, A; Gurkan, TT; Guven, R, 2023)
"Modern anticancer research has employed advanced computational techniques and artificial intelligence methods for drug discovery and development, along with the massive amount of generated clinical and in silico data over the last decades."	1.91	Computational Methods for Anticancer Drug Discovery; The MCT4 Paradigm. ( Eliopoulos, E; Papakonstantinou, E; Thireou, T; Vlachakis, D; Vlachoyiannopoulos, PG, 2023)
"Lactic acidosis is a feature of solid tumors and plays fundamental role(s) rendering cancer cells to adapt to diverse metabolic stresses, but the mechanism underlying its roles in redox homeostasis remains elusive."	1.91	A GSTP1-mediated lactic acid signaling promotes tumorigenesis through the PPP oxidative branch. ( Ahmad, M; Chen, C; He, Q; Hu, Y; Li, J; Lin, Y; Luo, H; Luo, Y; Sun, Y; Wang, B; Wu, D; Yang, Z; Zheng, L, 2023)
"Solid tumors have developed robust ferroptosis resistance."	1.91	HIF-1α drives resistance to ferroptosis in solid tumors by promoting lactate production and activating SLC1A1. ( Guan, Q; Qin, C; Qu, S; Su, W; Wang, Y; Wei, X; Xiang, J; Yang, Z; Yao, B; Zen, K; Zhao, D; Zhou, J, 2023)
"Cancers are complex, heterogeneous, dynamic and aggressive diseases exhibiting a series of characteristic biophysical traits which complement the original biological hallmarks of cancers favouring progressive growth, metastasis, and contributing to immune evasion and treatment resistance."	1.91	Hyperhydration of Cancers: A Characteristic Biophysical Trait Strongly Increasing O ( Piazena, H; Vaupel, P, 2023)
"A homotypic cancer cell membrane camouflaged zeolitic imidazolate framework (ZIF)-based nanoagent with co-loading of two inhibitors was developed, which could suppress the efflux of protons to induce intracellular acidic stress and down-regulate glutamine metabolism to reduce the energy supply."	1.72	A biomimetic ZIF nanoagent for synergistic regulation of glutamine metabolism and intracellular acidosis of cancer. ( Li, N; Lu, F; Pan, W; Tang, B; Wang, M, 2022)
"MYC-overexpressing or highly glycolytic tumors enhance PD-1 expression on T regulatory cells (Tregs)."	1.72	Lactic Acid Supports an Immunosuppressive Environment and Reduces ICB Response. ( , 2022)
"Communication between tumors and the stroma of tumor-draining lymph nodes (TDLN) exists before metastasis arises, altering the structure and function of the TDLN niche."	1.72	Tumor-Derived Lactic Acid Modulates Activation and Metabolic Status of Draining Lymph Node Stroma. ( Bhandare, P; da Costa, ASH; Davidson, S; Frezza, C; Haas, L; Hall, BA; Helal, M; Oskarsson, T; Pedro, L; Riedel, A; Schmitz, W; Shields, JD; Shorthouse, D; Swietlik, JJ; Wolf, E; Young, T, 2022)
"A majority of cancers fail to respond to immunotherapy due to the immunosuppressive tumor microenvironment (TME), and metabolic regulation of the TME has been a promising strategy to improve immunotherapy."	1.72	Nanodrug regulates lactic acid metabolism to reprogram the immunosuppressive tumor microenvironment for enhanced cancer immunotherapy. ( Cai, YJ; Li, B; Lin, MZ; Shuai, XT; Tian, LR; Xiao, ZC; Zhong, HH, 2022)
"Aggressive cancers commonly ferment glucose to lactic acid at high rates, even in the presence of oxygen."	1.72	Proton export upregulates aerobic glycolysis. ( Abrahams, D; Bui, MM; Epstein, T; Gillies, RJ; Johnson, J; Kam, Y; Lloyd, MC; Lopez, AS; Ordway, B; Ruiz, E; Russell, S; Swietach, P; Verduzco, D; Wojtkowiak, J; Xu, L, 2022)
"Most cancer cells switch their metabolism from mitochondrial oxidative phosphorylation to aerobic glycolysis to generate ATP and precursors for the biosynthesis of key macromolecules."	1.72	Discovery of novel human lactate dehydrogenase inhibitors: Structure-based virtual screening studies and biological assessment. ( Bufano, M; Canettieri, G; Coluccia, A; Di Magno, L; Di Pastena, F; Frati, L; La Regina, G; Nalli, M; Ripa, S; Silvestri, R, 2022)
"Conventional treatments for cancer, such as chemotherapy, surgical resection, and radiotherapy, have shown limited therapeutic efficacy, with severe side effects, lack of targeting and drug resistance for monotherapies, which limit their clinical application."	1.72	A multifunctional theranostics nanosystem featuring self-assembly of alcohol-abuse drug and photosensitizers for synergistic cancer therapy. ( Jiang, JL; Li, C; Lin, JF; Shao, JW; Shen, ZC; Wu, PY; Zhang, BC; Zhang, WZ; Zou, JJ, 2022)
"Therefore, the glycolytic process of tumors could represent a therapeutic target, and agents that modify the energy metabolism of tumor cells have therapeutic potential."	1.72	Resveratrol reduces lactate production and modifies the ovarian cancer immune microenvironment. ( Chen, J; Chen, JG; He, JH; He, SY; Huang, ST; Huang, ZH; Lin, WM; Ye, HY, 2022)
"Metabolic transformation of cancer cells leads to the accumulation of lactate and significant acidification in the tumor microenvironment."	1.62	Inhibition of Mitochondrial Metabolism Leads to Selective Eradication of Cells Adapted to Acidic Microenvironment. ( Dvořák, A; Koncošová, M; Křížová, I; Rimpelová, S; Ruml, T; Rumlová, M; Tomášová, P; Vítek, L; Vrzáčková, N; Zelenka, J, 2021)
"Using cultured mesenchymal and cancer cells, as well as mouse allograft models, we provide evidence that extracellular lactate can be utilized by fibroblasts to maintain tricarboxylic acid (TCA) cycle anaplerosis and non-essential amino acid biosynthesis through PC activity."	1.62	Fibroblast pyruvate carboxylase is required for collagen production in the tumour microenvironment. ( Cai, X; Cimino, FV; King, B; Pavlova, NN; Schwörer, S; Sizemore, GM; Thompson, CB, 2021)
"Exhausting lactate in tumors holds great promise for the reversal of the immunosuppressive tumor microenvironment (TME)."	1.62	Nanofactory for metabolic and chemodynamic therapy: pro-tumor lactate trapping and anti-tumor ROS transition. ( Chong, G; Dong, H; Gu, J; He, R; Li, Y; Liu, Y; Ruan, S; Xu, D; Yang, Y; Zang, J; Zhang, T; Zhao, Y; Zheng, X, 2021)
"Given its roles in oncogenesis, measuring intratumoural and systemic lactate levels has shown promise as a both predictive and prognostic biomarker in several cancer types."	1.62	The oncogenic and clinical implications of lactate induced immunosuppression in the tumour microenvironment. ( Davern, M; Donlon, NE; Donohoe, CL; Hayes, C, 2021)
"It is known to have anticancer properties."	1.62	Quercetin against MCF7 and CAL51 breast cancer cell lines: apoptosis, gene expression and cytotoxicity of nano-quercetin. ( Al-Amiery, AA; Al-Omar, MS; Alsharidah, M; Anwar, SS; Khan, RA; Mohammed, HA; Mohammed, SAA; Rugaie, OA; Sulaiman, GM; Tawfeeq, AT, 2021)
"In solid tumors, hypoxia can trigger aberrant expression of transcription factors and genes, resulting in abnormal biological functions such as altered energetic pathways in cancer cells."	1.56	Computational modeling to determine key regulators of hypoxia effects on the lactate production in the glycolysis pathway. ( Hashemzadeh, S; Omidi, Y; Rafii-Tabar, H; Shahmorad, S, 2020)
"While T cell-based cancer immunotherapies have shown great promise, there remains a need to understand how individual metastatic tumor environments impart local T cell dysfunction."	1.56	Characteristics of Malignant Pleural Effusion Resident CD8 ( Bruno, TC; Dhupar, R; Eisenberg, SH; Kammula, US; Liu, D; Lotze, MT; Luketich, JD; Monaco, SE; Okusanya, OT; Ruffin, AT; Soloff, AC, 2020)
"In patients with cancer having septic shock, LA >2."	1.56	Evaluating the Predictive Value of Lactate in Patients With Cancer Having Septic Shock. ( Hawari, FI; Nazer, LH; Rimawi, D, 2020)
"We hypothesize that DCA exerts its anticancer effects via depriving cancer of acetate benefits."	1.51	Dichloroacetate is an antimetabolite that antagonizes acetate and deprives cancer cells from its benefits: A novel evidence-based medical hypothesis. ( Abdel-Aziz, W; Abdel-Latif, HM; Aboonq, MS; Ahmed, NS; Almaramhy, HH; Ayat, M; Baghdadi, H; El Sayed, SM; El-Sawy, SA; Elshazley, M; Ibrahim, W; Mahmoud, AA, 2019)
" Compared to conventional agents, they increase bioavailability and efficacy."	1.51	Metabolite Responsive Nanoparticle-Protein Complex. ( Fruehauf, KR; Kim, TI; Nelson, EL; Patterson, JP; Shea, KJ; Wang, SW, 2019)
"To develop a cancer targeting lactate attenuator in vivo for cancer phototherapy and inhibition of HIF-1, we report an aptamer modified photo-responsive nanoparticle (labeled as Mn-D@BPFe-A) for lactate oxidation and cancer phototherapy."	1.48	An aptamer-Fe ( Chen, QY; Gao, J; Huang, T; Lu, WL; Yang, H; Zhao, Y, 2018)
"Conditions include Alzheimer's disease, atherosclerosis, diabetes mellitus, obesity, cancer, autoimmunity and psychosis, amongst others."	1.48	Optimise the microbial flora with milk and yoghurt to prevent disease. ( Morris, JA, 2018)
"KRAS mutated cancer cells were recently shown to rely on GOT1 to support long-term cell proliferation."	1.48	Inhibition of glutamate oxaloacetate transaminase 1 in cancer cell lines results in altered metabolism with increased dependency of glucose. ( Curbo, S; Karlsson, A; Krishnan, S; Li, F; Zhou, X, 2018)
"Irinotecan (IRN) (CPT-11) is a camptothecin derivative with low oral bioavailability due to active efflux by intestinal P-glycoprotein (p-gp) receptors."	1.48	Improvement of oral efficacy of Irinotecan through biodegradable polymeric nanoparticles through in vitro and in vivo investigations. ( Ahmad, N; Ahmad, R; Alam, MA; Jalees Ahmad, F; Umar, S, 2018)
"In models of brain cancer and AML, tumor growth was potently inhibited in vivo following IACS-010759 treatment at well-tolerated doses."	1.48	An inhibitor of oxidative phosphorylation exploits cancer vulnerability. ( Ackroyd, J; Agip, AA; Al-Atrash, G; Asara, J; Bandi, M; Bardenhagen, J; Bristow, C; Carrillo, CC; Carroll, C; Chang, E; Ciurea, S; Cross, JB; Czako, B; Daver, N; de Groot, JF; Deem, A; DePinho, RA; Di Francesco, ME; Do, MG; Dong, JW; Draetta, GF; Feng, N; Gao, G; Gay, J; Gera, S; Giuliani, V; Greer, J; Han, J; Han, L; Heffernan, TP; Henry, VK; Hirst, J; Huang, S; Jiang, Y; Jones, P; Kang, Z; Khor, T; Konoplev, S; Konopleva, M; Lin, YH; Liu, G; Lodi, A; Lofton, T; Ma, H; Mahendra, M; Marszalek, JR; Matre, P; McAfoos, T; Molina, JR; Morlacchi, P; Muller, F; Mullinax, R; Peoples, M; Petrocchi, A; Protopopova, M; Rodriguez-Canale, J; Serreli, R; Shi, T; Smith, M; Sun, Y; Tabe, Y; Theroff, J; Tiziani, S; Toniatti, C; Xu, Q; Zhang, Q, 2018)
"Upregulation of these steps in tumors likely underlies the Warburg effect."	1.48	Four Key Steps Control Glycolytic Flux in Mammalian Cells. ( Goglia, AG; Park, JO; Parsons, LR; Rabinowitz, JD; Sehgal, T; Tanner, LB; Toettcher, JE; Wei, MH; White, E, 2018)
"Patients with malignancy represent a particular challenge for the emergency department (ED) given their higher acuity, longer ED length of stay, and higher admission rate."	1.48	Serum Lactate and Mortality in Emergency Department Patients with Cancer. ( Buras, MR; Butler, RK; Chowdhury, Y; Lipinski, CA; Maher, SA; McLemore, RY; Temkit, M; Traub, SJ, 2018)
"In vitro anticancer effect and in vivo anticancer therapy was evaluated by CCK8 assay and MDA-MB231 tumor-bearing mice model."	1.48	Folate-receptor-targeted laser-activable poly(lactide- ( Cao, Y; Chen, Y; Gong, Y; Guo, Y; Li, P; Li, Y; Liu, F; Ran, H; Wang, Z, 2018)
"Active cancer patients who were diagnosed with pneumonia at the Emergency Department (ED) from 7/1/2014 to 12/31/2014 were consecutively included."	1.48	Prediction model for mortality in cancer patients with pneumonia: comparison with CURB-65 and PSI. ( Ahn, BK; Ahn, S; Kim, WY; Kim, YJ; Lee, JH; Lee, YS; Lim, KS; Seo, DW; Sohn, CH, 2018)
" CA4P-NPs reached an absolute bioavailability of 77."	1.46	Water-Soluble Combretastatin A4 Phosphate Orally Delivered via Composite Nanoparticles With Improved Inhibition Effect Toward S180 Tumors. ( Qiu, L; Shen, Y; Wu, L, 2017)
"Curcumin was reported to display pro-apoptotic effect via the inhibition of the JAK/STAT pathway, that is overexpressed in PEL cells, as consequence of virus infection."	1.46	Anticancer drug-loaded quantum dots engineered polymeric nanoparticles: Diagnosis/therapy combined approach. ( Belletti, D; Forni, F; Luppi, M; Pederzoli, F; Riva, G; Ruozi, B; Tosi, G; Vandelli, MA, 2017)
"Advanced stage cancer treatments are often invasive and painful-typically comprised of surgery, chemotherapy, and/or radiation treatment."	1.46	Distribution of PLGA-modified nanoparticles in 3D cell culture models of hypo-vascularized tumor tissue. ( Frieboes, HB; Huss, MK; Sims, LB; Steinbach-Rankins, JM, 2017)
" Thus, it was demonstrated that nanoencapsulation of 2-ME2 within PEGylated PLGA nanocarrier could improve its half-life and plasma concentration and thereby increase the tumour accumulation."	1.46	Influence of surface passivation of 2-Methoxyestradiol loaded PLGA nanoparticles on cellular interactions, pharmacokinetics and tumour accumulation. ( Menon, D; Nair, SV; Paul-Prasanth, B; Pillai, GJ, 2017)
"Cancers develop metabolic strategies to cope with their microenvironment often characterized by hypoxia, limited nutrient bioavailability and exposure to anticancer treatments."	1.46	Radiosynthesis and validation of (±)-[18F]-3-fluoro-2-hydroxypropionate ([18F]-FLac) as a PET tracer of lactate to monitor MCT1-dependent lactate uptake in tumors. ( Dehon, G; Frédérick, R; Grasso, D; Grégoire, V; Labar, D; Muccioli, GG; Sonveaux, P; Van Hée, VF, 2017)
"Among the types of vehicles for cancer vaccines, nanoparticles (NPs) are easier to produce with better scalability."	1.46	Nanotechnology-Based Cancer Vaccine. ( Alshamsan, A, 2017)
"Unearthing embryology-like processes in tumors may allow us to control organ-like tumor features such as tissue repair and revascularization and treat intratumoral heterogeneity."	1.46	Metabolic origins of spatial organization in the tumor microenvironment. ( Akkari, L; Carmona-Fontaine, C; Deforet, M; Joyce, JA; Thompson, CB; Xavier, JB, 2017)
"We enrolled 411 adult patients with severe sepsis and lactate ≥4."	1.43	Risk factors for mortality despite early protocolized resuscitation for severe sepsis and septic shock in the emergency department. ( Agarwal, A; Drumheller, BC; Gaieski, DF; Goyal, M; Mikkelsen, ME; Sante, SC; Weber, AL, 2016)
"Oxygenated cancer cells have a high metabolic plasticity as they can use glucose, glutamine and lactate as main substrates to support their bioenergetic and biosynthetic activities."	1.43	Lactate promotes glutamine uptake and metabolism in oxidative cancer cells. ( Brisson, L; Cacace, A; Dadhich, RK; De Saedeleer, CJ; Dhup, S; Fontenille, MJ; Pérez-Escuredo, J; Porporato, PE; Rodriguez, F; Sboarina, M; Sonveaux, P; Van Hée, VF, 2016)
"The strong anticancer activity of disulfiram is hindered by its rapid degradation in blood system."	1.43	The inhibitory effect of disulfiram encapsulated PLGA NPs on tumor growth: Different administration routes. ( Faghihi, S; Fasehee, H; Ghaffari, SH; Tavangar, SM; Zarrinrad, G, 2016)
"Circadian clock dysregulation promotes cancer growth."	1.43	PFKFB3 Control of Cancer Growth by Responding to Circadian Clock Outputs. ( Chen, L; Huo, Y; Li, H; Tang, Q; Wu, C; Yu, R; Zhang, C; Zhao, J; Zhao, Y, 2016)
"Targeted nanomedicine for cancer therapy has gained widespread popularity and is being extensively explored."	1.43	Development of hematin conjugated PLGA nanoparticle for selective cancer targeting. ( Amin, ML; Kim, D; Kim, S, 2016)
"Nanoparticle (NP)-based approaches to cancer drug delivery are challenged by the heterogeneity of the enhanced permeability and retention (EPR) effect in tumors and the premature attrition of payload from drug carriers during circulation."	1.43	Polymer-iron oxide composite nanoparticles for EPR-independent drug delivery. ( Abouelmagd, SA; Castanares, MA; Collins, DS; Kadasala, NR; Park, J; Wei, A; Yeo, Y, 2016)
"Most cancer cells predominantly produce ATP by maintaining a high rate of lactate fermentation, rather than by maintaining a comparatively low rate of tricarboxylic acid cycle, i."	1.43	Myristica fragrans Suppresses Tumor Growth and Metabolism by Inhibiting Lactate Dehydrogenase A. ( Choi, HJ; Choi, JH; Chung, TW; Ha, KT; Jung, YS; Kim, EY; Kim, KJ; Lee, SO; Park, MJ, 2016)
" In order to address this limitation, the present study was undertaken to investigate growth inhibitory effect of cisplatin in combination with a triterpenediol (3a, 24-dihydroxyurs-12-ene and 3a, 24-dihydroxyolean-12-ene, TPD) on human ovarian cancer cell line."	1.43	Improved efficacy of cisplatin in combination with a nano-formulation of pentacyclic triterpenediol. ( Alam, N; Andotra, SS; Gupta, PN; Khare, V; Koul, S; Kumar, A; Qayum, A; Sharma, PR; Singh, SK, 2016)
"Both cancer cells and activated T and NK immune cells display enhanced nutrient uptake and metabolism characteristic of the Warburg phenotype."	1.43	Lactate Wreaks Havoc on Tumor-Infiltrating T and NK Cells. ( Cleveland, JL; Scott, KE, 2016)
" In summary, PLGA and PLGA-Chi nanoparticles may be considered as an attractive and promising approach to enhance the bioavailability and activity of poorly water soluble compounds such as α-tocopherol and tocotrienols."	1.42	Cellular uptake, antioxidant and antiproliferative activity of entrapped α-tocopherol and γ-tocotrienol in poly (lactic-co-glycolic) acid (PLGA) and chitosan covered PLGA nanoparticles (PLGA-Chi). ( Alayoubi, A; Alqahtani, S; Astete, CE; Kaddoumi, A; Nazzal, S; Sabliov, CM; Shen, Y; Simon, L; Sylvester, PW; Xu, Z, 2015)
"Based on the metabolic features of cancer cells, live CTCs can be quantified indirectly through their lactic acid production."	1.42	Development of a microfluidic-based optical sensing device for label-free detection of circulating tumor cells (CTCs) through their lactic acid metabolism. ( Chiu, TK; Hsiao, HB; Hsieh, CH; Lei, KF; Wang, HM; Wu, MH, 2015)
"Lutein bioavailability is limited because of its poor aqueous solubility."	1.42	Biodegradable Poly (Lactic-co-Glycolic Acid)-Polyethylene Glycol Nanocapsules: An Efficient Carrier for Improved Solubility, Bioavailability, and Anticancer Property of Lutein. ( Arunkumar, R; Baskaran, V; Dharmesh, SM; Hirata, T; Manabe, Y; Prashanth, KVH; Sugawara, T, 2015)
"Oleanolic acid (OA) is a natural triterpenoid with anticancer properties, but its hydrophobic nature and poor aqueous solubility pose challenges in pharmaceutical formulation development."	1.42	Oleanolic Acid Loaded PEGylated PLA and PLGA Nanoparticles with Enhanced Cytotoxic Activity against Cancer Cells. ( Bonacucina, G; Casettari, L; Cespi, M; Kwok, PC; Lam, JK; Leung, GP; Man, DK; Palmieri, GF; Sze, SC, 2015)
"Intractable cancer-related pain complicated by a neuropathic component due to nerve impingement is poorly alleviated even by escalating doses of a strong opioid analgesic."	1.42	Novel polymeric bioerodable microparticles for prolonged-release intrathecal delivery of analgesic agents for relief of intractable cancer-related pain. ( Han, FY; Lam, AL; Smith, MT; Thurecht, KJ; Whittaker, AK, 2015)
"In many types of cancers this leads, even in the presence of oxygen, to the secretion of carbon equivalents (usually in the form of lactate) in the cell's surroundings, a feature known as the Warburg effect."	1.42	Quantitative constraint-based computational model of tumor-to-stroma coupling via lactate shuttle. ( Capuani, F; De Martino, A; De Martino, D; Marinari, E, 2015)
"Several cancers also showed an increase in genomic copy number of Usmg5 (gene encoding DAPIT), thereby providing strong correlative evidence for DAPIT possibly having oncogenic function in cancers."	1.42	DAPIT Over-Expression Modulates Glucose Metabolism and Cell Behaviour in HEK293T Cells. ( Cannino, G; Dufour, E; Kainulainen, H; Kontro, H; Rustin, P, 2015)
"Radiotherapy is a key component of cancer treatment."	1.42	Improving DNA double-strand repair inhibitor KU55933 therapeutic index in cancer radiotherapy using nanoparticle drug delivery. ( Caster, JM; Foote, M; Hyder, SN; Lara, H; Saripalli, S; Sethi, M; Tian, X; Wagner, KT; Wang, AZ; Wang, E; Zhang, L, 2015)
"When wild-type KISS1 metastasis suppressor is expressed, aerobic glycolysis decreases and oxidative phosphorylation predominates."	1.40	Metastasis suppressor KISS1 seems to reverse the Warburg effect by enhancing mitochondrial biogenesis. ( Ballinger, SW; Beck, BH; Denning, WL; Dhar, A; Diers, AR; Feeley, KP; Iwakuma, T; Landar, A; Liu, W; Nash, KT; Pounds, KM; Vaidya, KS; Welch, DR, 2014)
" However, its molecular form shows poor uptake and bioavailability and limited ability to reach its target mitochondria."	1.40	Mito-DCA: a mitochondria targeted molecular scaffold for efficacious delivery of metabolic modulator dichloroacetate. ( Dhar, S; Harn, DA; Marrache, S; Pathak, RK, 2014)
"Particle-based cancer vaccines prepared from biodegradable polymers are a potentially attractive way of delivering antigen alone, or in combination with adjuvant molecules, to dendritic cells (DC)."	1.40	Production of antigen-loaded biodegradable nanoparticles and uptake by dendritic cells. ( Geary, SM; Joshi, VB; Salem, AK, 2014)
"The mechanisms that allow cancer cells to adapt to the typical tumor microenvironment of low oxygen and glucose and high lactate are not well understood."	1.40	Cell surface lactate receptor GPR81 is crucial for cancer cell survival. ( Arumugam, T; Burns, WR; Cruz-Monserrate, Z; Deng, D; Gomez, S; Liu, SH; Logsdon, CD; Philip, B; Ramachandran, V; Roland, CL; Wang, H, 2014)
"Many cancer cells rely more on aerobic glycolysis (the Warburg effect) than mitochondrial oxidative phosphorylation and catabolize glucose at a high rate."	1.40	Tyr-94 phosphorylation inhibits pyruvate dehydrogenase phosphatase 1 and promotes tumor growth. ( Aguiar, M; Arellano, M; Boggon, TJ; Chung, TW; Elf, S; Fan, J; Gu, TL; Hitosugi, T; Kang, HB; Khoury, HJ; Khuri, FR; Lonning, S; Shan, C; Shin, DM; Xie, J, 2014)
"Neutropenia is a common chemotherapy-derived complication in cancer patients, in whom the prevalence of sepsis ranges from 12."	1.40	[Serum lactate as a biomarker of severe sepsis in children with cancer, neutropenia and fever]. ( Huelgas-Plaza, AC; Miranda-Novales, MG; Pacheco-Rosas, DO, 2014)
"Synergistic release of platinum anticancer drugs and O2 can be achieved in an H2O2-responsive nanocarrier incorporated with catalase."	1.40	An H₂O₂-responsive nanocarrier for dual-release of platinum anticancer drugs and O₂: controlled release and enhanced cytotoxicity against cisplatin resistant cancer cells. ( Chen, H; Guo, Z; He, W, 2014)
"Double targeting of nanoparticles to tumors by different mechanisms could be a promising translational approach for the management of therapeutic treatment and personalized therapy."	1.40	Comparison of active, passive and magnetic targeting to tumors of multifunctional paclitaxel/SPIO-loaded nanoparticles for tumor imaging and therapy. ( Danhier, F; Gallez, B; Jacobs, D; Po, C; Préat, V; Schleich, N; Ucakar, B, 2014)
"Poor availability in deep-seated solid tumors is a significant challenge that limits the effectiveness of currently used anticancer drugs."	1.40	Nano-engineered mesenchymal stem cells as targeted therapeutic carriers. ( O'Brien, TD; Prabha, S; Sadhukha, T, 2014)
"NK cells from LDH-A-depleted tumors had improved cytolytic function."	1.39	Tumor-derived lactate modifies antitumor immune response: effect on myeloid-derived suppressor cells and NK cells. ( Huang, Y; Husain, Z; Seth, P; Sukhatme, VP, 2013)
"Although intrinsic oxidative stress in cancer cells is high, it may be prevented from reaching progressively increasing levels that are cytotoxic to cancer cells."	1.39	Warburg effect increases steady-state ROS condition in cancer cells through decreasing their antioxidant capacities (anticancer effects of 3-bromopyruvate through antagonizing Warburg effect). ( Abdelaal, EA; Abdelmoaty, MA; Ahmed, NS; El Sawy, SA; El Sayed, SM; Fouad, AM; Gabr, AG; Hashim, MS; Hemdan, SB; Kadry, ZM; Mahmoud, AA; Nabo, MM; Omran, FM; Yousif, RS, 2013)
"Many cancer cells have increased rates of aerobic glycolysis, a phenomenon termed the Warburg effect."	1.39	M2 isoform of pyruvate kinase is dispensable for tumor maintenance and growth. ( Chene, P; Cortés-Cros, M; Ferretti, S; Gounarides, JS; Haberkorn, A; Hemmerlin, C; Hofmann, F; Muller, A; Sellers, WR; Yin, H; Zhang, J, 2013)
"It is feasible to dose cytotoxic anti-cancer drugs as a nanoparticle-based depot formulation, especially when combined with an advanced prodrug strategy."	1.39	A nanoparticle depot formulation of 4-(N)-stearoyl gemcitabine shows a strong anti-tumour activity. ( Cui, Z; Kumar, A; Lansakara-P, DS; Li, X; Zhu, S, 2013)
"Inefficiency of cancer chemotherapy to improve life expectancy in majority of patients raises serious concern and warrants development of novel therapeutic strategies."	1.39	Nanoparticle mediated co-delivery of paclitaxel and a TLR-4 agonist results in tumor regression and enhanced immune response in the tumor microenvironment of a mouse model. ( Bhaskar, S; Roy, A; Singh, MS; Upadhyay, P, 2013)
"The detection of a small number of circulating tumor cells (CTCs) is important, especially in the early stages of cancer."	1.38	Nanotextured substrates with immobilized aptamers for cancer cell isolation and cytology. ( Allen, PB; Bachoo, R; Ellington, AD; Iqbal, SM; Kim, YT; Li, N; Mahmood, MA; Wan, Y, 2012)
"Whereas most oxidative cancer cells import lactate through MCT1 to fuel mitochondrial respiration, the role of MCT1 in glycolysis-derived lactate efflux remains less clear."	1.38	Regulation of monocarboxylate transporter MCT1 expression by p53 mediates inward and outward lactate fluxes in tumors. ( Boidot, R; Dessy, C; Feron, O; Le Breton, A; Lizard-Nacol, S; Meulle, A; Sonveaux, P; Végran, F, 2012)
"Since cancer cells may also express α(v)β(3) integrin, the entrapping of RGD-nanoparticles into the tumor interstitial fluid may yet be facilitated through direct binding to cancer cells."	1.38	Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles. ( Danhier, F; Feron, O; Jérôme, C; Marchand-Brynaert, J; Pourcelle, V; Préat, V, 2012)
"5-Fluorouracil (5FU) was successfully entrapped within poly(lactide-co-glycolide) (PLGA) and hydroyapatite (HA) composite microspheres using the emulsification/solvent extraction technique."	1.38	5-Fluorouracil encapsulated HA/PLGA composite microspheres for cancer therapy. ( Li, Y; Lin, Y; Ooi, CP, 2012)
"Recent studies have suggested that cancer cells behave as metabolic parasites, by inducing oxidative stress in adjacent normal fibroblasts."	1.38	Mitochondrial fission induces glycolytic reprogramming in cancer-associated myofibroblasts, driving stromal lactate production, and early tumor growth. ( Ando', S; Aquila, S; Casimiro, MC; Guido, C; Howell, A; Lin, Z; Lisanti, MP; Martinez-Outschoorn, UE; Pestell, RG; Sotgia, F; Whitaker-Menezes, D; Zimmers, TA, 2012)
"LNCaP prostate cancer cells were also cultured on 3D A."	1.37	Engineered silk fibroin protein 3D matrices for in vitro tumor model. ( Hutmacher, DW; Kundu, SC; Mandal, M; Russell, PJ; Soekmadji, C; Talukdar, S, 2011)
"Many peptide-based cancer vaccines have been tested in clinical trials with a limited success, mostly due to difficulties associated with peptide stability and delivery, resulting in inefficient antigen presentation."	1.37	Enhanced presentation of MHC class Ia, Ib and class II-restricted peptides encapsulated in biodegradable nanoparticles: a promising strategy for tumor immunotherapy. ( Bogin, V; Carrier, E; Hayden, M; Kumar, V; Ma, W; Messmer, D; Minev, B; Ozkan, C; Ozkan, M; Schroter, S; Smith, T; Zhang, Y, 2011)
"As PKM2 universally expresses in cancer cells and dictates the last rate-limiting step of glycolysis vital for cancer cell proliferation and survival, enantiomeric shikonin and alkannin may have potential in future clinical application."	1.37	Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2. ( Chen, J; Hu, X; Jiang, Z; Wang, B; Wang, Y; Xie, J, 2011)
"Human cancers consume larger amounts of glucose compared to normal tissues with most being converted and excreted as lactate despite abundant oxygen availability (Warburg effect)."	1.37	Posttranslational modification of 6-phosphofructo-1-kinase as an important feature of cancer metabolism. ( Legiša, M; Šmerc, A; Sodja, E, 2011)
"In solid malignant tumors, lactate has been identified as a prognostic parameter for metastasis and overall survival of patients."	1.37	Lactate enhances motility of tumor cells and inhibits monocyte migration and cytokine release. ( Goetze, K; Ksiazkiewicz, M; Kunz-Schughart, LA; Mueller-Klieser, W; Walenta, S, 2011)
"Interestingly, cancer cells with stable knockdown of endogenous LDH-A and rescue expression of a catalytic hypomorph LDH-A mutant, Y10F, demonstrate increased respiration through mitochondrial complex I to sustain glycolysis by providing NAD(+)."	1.37	Tyrosine phosphorylation of lactate dehydrogenase A is important for NADH/NAD(+) redox homeostasis in cancer cells. ( Boggon, TJ; Chen, GZ; Chen, J; Chung, TW; Fan, J; Ge, Q; Gu, TL; Hitosugi, T; Kang, S; Khuri, FR; Lonial, S; Polakiewicz, RD; Xie, J, 2011)
"Furthermore, anaerobic metabolism in cancer cells bears similarity to homo-fermentative lactic acid bacteria, however very little is known about an alternative pathway that may drive adenosine triphosphate (ATP) production independent of glycolysis."	1.36	Evaluation of endogenous acidic metabolic products associated with carbohydrate metabolism in tumor cells. ( Mazzio, EA; Smith, B; Soliman, KF, 2010)
"Doxorubicin (DOX) is an anticancer drug with an intracellular site of action in the nucleus."	1.36	Intracellular trafficking of nuclear localization signal conjugated nanoparticles for cancer therapy. ( Misra, R; Sahoo, SK, 2010)
"Both one-step and three-step cancer-targeting strategies were tested on the LS174T human colon cancer cell line."	1.36	Synthesizing and binding dual-mode poly (lactic-co-glycolic acid) (PLGA) nanobubbles for cancer targeting and imaging. ( Hinkle, GH; Huang, J; Martin, EW; Povoski, SP; Qin, R; Xu, JS; Xu, RX, 2010)
"Antiangiogenic cancer therapy can be achieved through the targeted delivery of antiangiogenic agents to the endothelial cells of tumor neovasculature."	1.36	Peptide-conjugated biodegradable nanoparticles as a carrier to target paclitaxel to tumor neovasculature. ( Chen, HZ; Fang, C; Lu, Q; Xie, J; Yu, DH, 2010)
"For the cancer image and therapy, fluorescence dye, tetramethylrhodamine isothiocyanate (TRITC), or anticancer drug, camptothecin (CPT), was efficiently encapsulated into the pH-responsive polymeric micelles (pH-PMs) by a simple solvent casting method."	1.36	Tumoral acidic pH-responsive MPEG-poly(beta-amino ester) polymeric micelles for cancer targeting therapy. ( Bae, SM; Jeong, SY; Kim, IS; Kim, JH; Kim, K; Kim, MS; Kwon, IC; Lee, DS; Lee, H; Min, KH; Park, RW; Park, S; Shin, H, 2010)
" The IC(50) values were lowered by a factor of approximately 3 for FA-NanoGSE compared to the free drug, indicating substantially enhanced bioavailability to the tumor cells, sparing the normal ones."	1.36	Folate targeted polymeric 'green' nanotherapy for cancer. ( Binulal, NS; Manzoor, K; Menon, D; Mony, U; Nair, S; Narayanan, S, 2010)
" The oral bioavailability can be enhanced from 3."	1.35	Poly(lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of Docetaxel. ( Anitha, P; Feng, SS; Gan, CW; Mei, L; Zhou, W, 2009)
"Understanding cancer cell metabolism and targeting associated pathways is a field of increasing interest."	1.35	Fingerprint of cell metabolism in the experimentally observed interstitial pH and pO2 in solid tumors. ( Kohandel, M; Milosevic, M; Molavian, HR; Sivaloganathan, S, 2009)
"Moreover, the stimulatory effect of anoxia on glycolytic flux was inversely correlated to the relative reliance on aerobic glycolysis."	1.35	Aerobic glycolysis in cancers: implications for the usability of oxygen-responsive genes and fluorodeoxyglucose-PET as markers of tissue hypoxia. ( Busk, M; Bussink, J; Horsman, MR; Kristjansen, PE; Overgaard, J; van der Kogel, AJ, 2008)
"This may be because these aggressive cancers have a hypoxic core which generates signals that activate angiogenesis which enables the supply of nutrients and oxygen to a rapidly growing outer oxidative shell."	1.33	Metabolic depression: a response of cancer cells to hypoxia? ( Brunner, S; Buchanan, M; Guppy, M, 2005)
"Paclitaxel is one of the best anticancer drugs, which has excellent therapeutic effects against a wide spectrum of cancers."	1.33	Nanoparticles of poly(lactide)/vitamin E TPGS copolymer for cancer chemotherapy: synthesis, formulation, characterization and in vitro drug release. ( Feng, SS; Zhang, Z, 2006)
"The conditions included seizures, inflammatory changes, and proven metabolic disorders."	1.33	The significance of elevated CSF lactate. ( Chow, SL; Clayton, PT; Cleary, MA; Leonard, JV; Rooney, ZJ, 2005)
"The buccal cancer model was established in 64 golden hamsters, which were divided randomly into two groups for 32 animals in each group, CDDP-PLA-PEG-NP (6."	1.33	[Experimental study of cisplatin loaded polylactic acid-polyethylene glycol nano-particles for targeting oral carcinoma]. ( Chen, R; Chen, SW; Wan, YM; Yang, K, 2005)
"It has been known for decades that cancer cells produce excessive amounts of lactic acid."	1.31	Dysfunctional mitochondria, not oxygen insufficiency, cause cancer cells to produce inordinate amounts of lactic acid: the impact of this on the treatment of cancer. ( John, AP, 2001)
"However, although most solid tumors maintain their intracellular pH (pHi) within a narrow range to provide a favorable environment for various intracellular activities, their extracellular pH (pHe) is on average about 0."	1.30	Causes and consequences of acidic pH in tumors: a magnetic resonance study. ( Griffiths, JR; McSheehy, PM; Stubbs, M, 1999)
"Accordingly, enhanced IFP in tumors is the result of high rates of tumor glycolysis, and enhancement of IFP is limited by MVP."	1.30	A biophysical basis of enhanced interstitial fluid pressure in tumors. ( Rutz, HP, 1999)
"Cancer or neoplasia occurs, according A."	1.29	Force, development, and neoplasia: development from another perspective as illustrated through a study of in vitro plant development from neoplasm. ( Lieber, MM, 1996)
"It is suggested that acid conditions in tumors might allow the development of new and relatively specific types of therapy which are directed against mechanisms which regulate pHi under acid conditions."	1.28	Acid pH in tumors and its potential for therapeutic exploitation. ( Rotin, D; Tannock, IF, 1989)
"Hydrochloric acid has a greater effect than lactic acid."	1.28	[Temperature, pH value, acid load and filtrability of normal human erythrocytes: in vitro studies--possible significance for hyperthermic hyperacidotic tumor therapy]. ( Barnikol, WK, 1989)
"Purified lymphocyte preparations from cancer patients were less responsive to the mitogen phytohaemagglutinin (PHA) than were lymphocytes from healthy donors as measured by [3H]-thymidine uptake over periods in culture up to 96 hours."	1.27	Lymphocyte lactate dehydrogenase isoenzymes in association with depressed mitogen responsiveness. ( Collins, PB; Hannigan, B; Johnson, AH; Moriarty, M, 1984)
"A newly established cancer marker, the PFK inhibition test, has been further examined for its capacity to detect malignant neoplasms irrespective of the organs in which cancer cells start proliferating."	1.27	PFK inhibition test for cancer detection: clinical applications and mechanisms of PFK inhibition. ( Kituta, T; Kobayashi, K; Nakajima, Y; Nakamura, K; Nakamura, Y; Uchida, T, 1987)
"Lactate in cancerous sera was 1."	1.27	Decrease of serum buffering capacity associated with malignant neoplasms. ( Koide, A; Nakajima, Y; Nakamura, K; Nakamura, Y; Ogiwara, H, 1988)

Research

Studies (572)

Authors

Clinical Trials (10)

Trial Overview

Trial Outcomes

To Determine Whether the Prophylactic Use of a Topical Urea/Lactic Acid Cream Can Decrease the Incidence/Severity of Capecitabine-caused Palmar-plantar Erythrodysesthesia

Timeframe	Studies, this research(%)	All Research%
pre-1990	37 (6.47)	18.7374
1990's	13 (2.27)	18.2507
2000's	50 (8.74)	29.6817
2010's	318 (55.59)	24.3611
2020's	154 (26.92)	2.80

Authors	Studies
Luo, Y	3
Li, L	4
Chen, X	5
Gou, H	1
Yan, K	1
Xu, Y	4
Liu, X	2
Yamaguchi, K	1
Takane, K	1
Zhu, C	1
Hirata, M	1
Hikiba, Y	1
Maeda, S	1
Furukawa, Y	1
Ikenoue, T	1
Koncošová, M	1
Vrzáčková, N	2
Křížová, I	1
Tomášová, P	1
Rimpelová, S	1
Dvořák, A	1
Vítek, L	1
Rumlová, M	1
Ruml, T	2
Zelenka, J	2
Wang, ZH	1
Peng, WB	1
Zhang, P	2
Yang, XP	1
Zhou, Q	1
Al-Nemrawi, NK	1
Altawabeyeh, RM	1
Darweesh, RS	1
Schwörer, S	1
Pavlova, NN	1
Cimino, FV	1
King, B	1
Cai, X	1
Sizemore, GM	1
Thompson, CB	3
Zhang, Q	3
Jeppesen, DK	1
Higginbotham, JN	1
Graves-Deal, R	1
Trinh, VQ	1
Ramirez, MA	1
Sohn, Y	1
Neininger, AC	1
Taneja, N	1
McKinley, ET	1
Niitsu, H	1
Cao, Z	2
Evans, R	1
Glass, SE	1
Ray, KC	1
Fissell, WH	1
Hill, S	1
Rose, KL	1
Huh, WJ	1
Washington, MK	1
Ayers, GD	1
Burnette, DT	1
Sharma, S	1
Rome, LH	1
Franklin, JL	1
Lee, YA	1
Liu, Q	4
Coffey, RJ	1
He, R	1
Zang, J	1
Zhao, Y	6
Liu, Y	6
Ruan, S	1
Zheng, X	1
Chong, G	1
Xu, D	1
Yang, Y	6
Zhang, T	1
Gu, J	1
Dong, H	1
Li, Y	7
Govoni, M	1
Rossi, V	1
Di Stefano, G	1
Manerba, M	1
Silva, A	1
Antunes, B	1
Batista, A	1
Pinto-Ribeiro, F	1
Baltazar, F	4
Afonso, J	3
Wang, M	2
Lu, F	1
Li, N	2
Pan, W	1
Tang, B	1
Watson, MJ	2
Delgoffe, GM	2
Ippolito, L	2
Sonveaux, P	10
Chiarugi, P	2
Shams, A	1
Shabani, R	1
Asgari, H	1
Karimi, M	1
Najafi, M	1
Asghari-Jafarabadi, M	1
Razavi, SM	1
Miri, SR	1
Abbasi, M	1
Mohammadi, A	1
Koruji, M	1
Goswami, KK	1
Banerjee, S	2
Bose, A	1
Baral, R	1
Delahunty, I	1
Li, J	6
Jiang, W	1
Lee, C	1
Yang, X	2
Kumar, A	4
Liu, Z	5
Zhang, W	3
Xie, J	6
Heneberg, P	1
Ercin, E	1
Kecel-Gunduz, S	1
Gok, B	1
Aydin, T	1
Budama-Kilinc, Y	1
Kartal, M	1
Riedel, A	1
Helal, M	1
Pedro, L	1
Swietlik, JJ	1
Shorthouse, D	1
Schmitz, W	1
Haas, L	1
Young, T	1
da Costa, ASH	1
Davidson, S	1
Bhandare, P	1
Wolf, E	1
Hall, BA	1
Frezza, C	1
Oskarsson, T	1
Shields, JD	1
Zhang, C	5
Quinones, A	1
Le, A	1
Stransky, N	1
Huber, SM	1
Li, S	3
Lan, X	1
Tan, L	1
Lv, KP	1
Huang, Z	1
Gou, L	1
Wan, J	2
Meng, X	1
Tang, XD	1
Lü, KL	1
Yu, J	3
Du, HJ	1
Fan, CQ	1
Chen, L	6
Jena, BC	1
Das, CK	1
Banerjee, I	1
Bharadwaj, D	1
Majumder, R	1
Das, S	1
Biswas, A	1
Kundu, M	1
Roy, PK	1
Kundu, CN	1
Mandal, M	2
Cuenca, JA	1
Manjappachar, NK	1
Ramírez, CM	1
Hernandez, M	1
Martin, P	1
Gutierrez, C	1
Rathi, N	1
Sprung, CL	1
Price, KJ	1
Nates, JL	1
Ling, J	1
Chang, Y	1
Yuan, Z	2
Chen, Q	3
He, L	1
Chen, T	2
Decking, SM	1
Bruss, C	1
Babl, N	1
Bittner, S	1
Klobuch, S	1
Thomas, S	2
Feuerer, M	1
Hoffmann, P	2
Dettmer, K	2
Oefner, PJ	2
Renner, K	3
Kreutz, M	8
Tian, LR	1
Lin, MZ	1
Zhong, HH	1
Cai, YJ	1
Li, B	3
Xiao, ZC	1
Shuai, XT	1
Gao, Y	1
Zhou, H	1
Liu, G	4
Wu, J	2
Yuan, Y	3
Shang, A	1
Bononi, G	1
Masoni, S	1
Di Bussolo, V	1
Tuccinardi, T	2
Granchi, C	3
Minutolo, F	3
Elia, I	1
Rowe, JH	1
Johnson, S	1
Joshi, S	1
Notarangelo, G	1
Kurmi, K	1
Weiss, S	1
Freeman, GJ	1
Sharpe, AH	1
Haigis, MC	2
Russell, S	1
Xu, L	2
Kam, Y	1
Abrahams, D	1
Ordway, B	1
Lopez, AS	1
Bui, MM	1
Johnson, J	1
Epstein, T	2
Ruiz, E	1
Lloyd, MC	1
Swietach, P	2
Verduzco, D	1
Wojtkowiak, J	1
Gillies, RJ	1
Di Magno, L	1
Coluccia, A	1
Bufano, M	1
Ripa, S	1
La Regina, G	1
Nalli, M	1
Di Pastena, F	1
Canettieri, G	1
Silvestri, R	1
Frati, L	1
Bao, Y	1
Maeki, M	1
Ishida, A	1
Tani, H	1
Tokeshi, M	1
Lee, SE	1
Lee, CM	1
Won, JE	2
Jang, GY	1
Lee, JH	2
Park, SH	2
Kang, TH	2
Han, HD	2
Park, YM	2
Certo, M	3
Llibre, A	1
Lee, W	2
Mauro, C	5
Li, X	10
Zhang, B	2
Lin, X	2
Fu, X	1
An, Y	1
Zou, Y	2
Wang, JX	2
Wang, Z	4
Yu, T	1
Feng, Q	1
Yu, X	1
Huang, T	2
Chen, J	7
Wang, J	8
Wilhelm, J	1
Song, J	1
Li, W	3
Sun, Z	2
Sumer, BD	1
Fu, YX	1
Gao, J	3
Dong, Z	1
Wang, C	5
Gong, Y	3
Zhang, Y	10
Fan, Q	1
Hao, Y	1
Li, Q	4
Wu, Y	4
Zhong, X	2
Yang, K	4
Feng, L	2
Hardie, DG	1
Wen, L	3
Tan, C	1
Ma, S	4
Wu, PY	1
Shen, ZC	1
Jiang, JL	1
Zhang, BC	1
Zhang, WZ	1
Zou, JJ	1
Lin, JF	1
Li, C	1
Shao, JW	1
Huang, ST	1
Chen, JG	1
He, JH	1
Lin, WM	1
Huang, ZH	1
Ye, HY	1
He, SY	1
Truszkiewicz, A	1
Bartusik-Aebisher, D	1
Zalejska-Fiolka, J	1
Kawczyk-Krupka, A	1
Aebisher, D	1
Huang, L	3
Gu, Y	1
Cang, W	1
Sun, P	1
Xiang, Y	1
Apostolova, P	1
Pearce, EL	1
Lin, J	3
Kwok, HF	1
Lin, Y	3
Jedlička, M	1
Feglarová, T	1
Janstová, L	1
Hortová-Kohoutková, M	1
Frič, J	1
Paul, S	1
Ghosh, S	1
Kumar, S	2
Dragulska, SA	1
Poursharifi, M	1
Chen, Y	4
Wlodarczyk, MT	1
Acosta Santiago, M	1
Dottino, P	1
Martignetti, JA	1
Mieszawska, AJ	2
Sharma, D	2
Singh, M	2
Rani, R	2
Zhao, J	6
Tian, Z	3
Zhao, S	3
Feng, D	2
Guo, Z	6
Zhu, Y	4
Xu, F	5
Zhu, J	2
Hu, J	3
Jiang, T	2
Qu, Y	3
Chen, D	2
Liu, L	3
Wang, H	6
Wang, B	6
Jiang, J	2
Song, A	2
Wang, X	2
Yao, C	3
Dai, H	2
Xu, J	2
Ma, Q	2
Li, R	3
Sun, L	3
Gao, W	3
Liu, J	7
Yu, H	2
Xu, ZP	2
Goldberg, FW	2
Kettle, JG	2
Lamont, GM	2
Buttar, D	2
Ting, AKT	2
McGuire, TM	2
Cook, CR	2
Beattie, D	2
Morentin Gutierrez, P	2
Kavanagh, SL	2
Komen, JC	2
Kawatkar, A	2
Clark, R	2
Hopcroft, L	2
Hughes, G	2
Critchlow, SE	2
Wu, C	2
Shi, J	3
Zhang, L	5
Yu, L	2
Peng, W	1
Zhang, S	1
He, Y	1
de Araújo Júnior, RF	1
Cavalcante, RS	1
Yu, Z	1
Schomann, T	1
Gu, Z	1
Eich, C	1
Cruz, LJ	2
Lv, X	1
Lv, Y	1
Dai, X	1
Gnocchi, D	2
Sabbà, C	2
Mazzocca, A	2
Negron, K	1
Kwak, G	1
Li, H	4
Huang, YT	1
Chen, SW	2
Tyler, B	1
Eberhart, CG	1
Hanes, J	1
Suk, JS	1
Wang, JH	1
Mao, L	1
Zhang, X	7
Wu, M	3
Wen, Q	1
Yu, SC	1
Gupta, R	1
Kumar, V	3
Byun, JK	1
Wang, K	1
Chen, ZN	1
Jacquet, P	1
Stéphanou, A	1
Rong, Y	1
Dong, F	1
Zhang, G	3
Tang, M	1
Zhao, X	3
Tao, P	1
Cai, H	1
Fan, H	2
Yang, F	1
Xiao, Z	1
Luo, H	2
Chen, H	5
Chen, Z	1
Xiao, Y	1
Bridgewater, HE	1
Bolitho, EM	1
Romero-Canelón, I	1
Sadler, PJ	1
Coverdale, JPC	1
Andreucci, E	1
Fioretto, BS	1
Rosa, I	1
Matucci-Cerinic, M	1
Biagioni, A	1
Romano, E	1
Calorini, L	1
Manetti, M	1
Khakpoor-Koosheh, M	1
Rostamian, H	1
Masoumi, E	1
Jafarzadeh, L	1
Fallah-Mehrjardi, K	1
Javad Tavassolifar, M	1
Noorbakhsh, F	1
Mirzaei, HR	1
Hadjati, J	1
Rezaei, N	1
Wang, R	1
Ni, C	1
Lou, X	1
Wang, L	5
Yao, X	2
Duan, X	2
Li, P	3
Qin, Z	1
Wang, T	1
Ye, Z	1
Li, Z	6
Jing, DS	1
Fan, GX	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Evaluation of the Safety and Efficacy of Esperanza Extract (Petiveria Alliacea) in Patients With Metastatic Gastrointestinal Tumors and Acute Leukemia[NCT05587088]	Phase 1/Phase 2	82 participants (Anticipated)	Interventional	2022-12-15	Not yet recruiting
A Prospective Long-term Observational Study in Patients With Monoclonal Gammopathy of Undetermined Significance[NCT05539079]		2,000 participants (Anticipated)	Observational	2023-09-06	Recruiting
Trial of Dichloroacetate (DCA) in Glioblastoma Multiforme (GBM)[NCT05120284]	Phase 2	40 participants (Anticipated)	Interventional	2022-07-01	Recruiting
A Pilot Study Evaluating a Ketogenic Diet Concomitant to Nivolumab and Ipilimumab in Patients With Metastatic Renal Cell Carcinoma[NCT05119010]		60 participants (Anticipated)	Interventional	2023-03-24	Recruiting
Comparison of the Effects of Total Intravenous Anesthesia and Inhalation Anesthesia on Lymphocytes in Patients Undergoing Colorectal Cancer Resection and the Mechanism Involved: a Single-center, Randomized, Prospective Study[NCT03193710]		260 participants (Anticipated)	Observational	2017-09-01	Recruiting
Effect of Very Low Carbohydrate Diet to Glasgow Prognostic Score, Serum Lactate and TNF Alpha on Colorectal Cancer Patients With Best Supportive Care[NCT03221920]		26 participants (Anticipated)	Interventional	2017-08-05	Not yet recruiting
A Phase II, Randomised Controlled Trial to Evaluate the Efficacy and Safety of Moisturising Creams With or Without Palm-oil-derived Vitamin E Concentrate in Addition to Urea-based Cream or Urea-based Cream Alone in Capecitabine-associated Palmar-Plantar E[NCT05939726]		90 participants (Anticipated)	Interventional	2023-05-16	Recruiting
A Phase III Randomized, Placebo-controlled, Double-blind Trial to Determine the Effectiveness of a Urea/Lactic Acid-Based Topical Keratolytic Agent and Vitamin B-6 for Prevention of Capecitabine-Induced Hand and Foot Syndrome[NCT00296036]	Phase 3	137 participants (Actual)	Interventional	2006-06-30	Completed
The Role of Pyruvate Kinase M2 in Growth, Invasion and Drug Resistance in Human Urothelial Carcinoma[NCT01968928]		25 participants (Anticipated)	Observational [Patient Registry]	2014-01-31	Not yet recruiting
What Are the Factors Affecting Neoadjuvant Chemotherapy Efficacy in Breast Cancer? A Non-invasive in Vivo Study Using Specialist Magnetic Resonance (MR) Methods[NCT03501394]		25 participants (Anticipated)	Interventional	2018-05-02	Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

A patient self-reported hand-foot syndrome (HFSD), also known as palmar-plantar erythrodysesthesia, was completed daily while applying the cream. Patients rated skin severity symptoms individually in their hands and in their feet. Definitions of symptoms, which were based on Common Terminology Criteria for Adverse Events (CTCAE) v3.0, were provided to patients. The number of patients reporting moderate to severe symptoms in either hands or feet were tabulated and percentages are reported. (NCT00296036)
Timeframe: First 3 weeks of treatment

To Evaluate the Potential Toxicity of Urea/Lactic Acid Cream

Intervention	percentage of participants (Number)
Urea/Lactic Acid Cream	13.6
Placebo Cream	10.2

Frequency and severity of adverse events reported by patients in weekly diary and evaluated through clinical assessment by NCI CTCAE v3.0. The number of patients reporting grade 3 or higher events are reported in this outcome measure. For a full list of all events, please refer to the Adverse Events section of this report. (NCT00296036)
Timeframe: Up to 4, 21-day cycles

Article	Year
Effects of lactate in immunosuppression and inflammation: Progress and prospects. International reviews of immunology, 2022, Volume: 41, Issue:1 Topics: Humans; Immunosuppression Therapy; Inflammation; Lactic Acid; Neoplasms; Receptors, G-Protein-Couple	2022
Lactate in the tumour microenvironment: From immune modulation to therapy. EBioMedicine, 2021, Volume: 73 Topics: Animals; Biological Transport; Biomarkers; Disease Management; Disease Susceptibility; Energy Metabo	2021
In Vivo Anticancer Activity of AZD3965: A Systematic Review. Molecules (Basel, Switzerland), 2021, Dec-29, Volume: 27, Issue:1 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Disease Management; Disease Progression; Drug Eval	2021
Fighting in a wasteland: deleterious metabolites and antitumor immunity. The Journal of clinical investigation, 2022, 01-18, Volume: 132, Issue:2 Topics: Adenosine; Animals; Humans; Immunotherapy; Kynurenine; Lactic Acid; Neoplasms; Reactive Oxygen Speci	2022
Lactic acid in alternative polarization and function of macrophages in tumor microenvironment. Human immunology, 2022, Volume: 83, Issue:5 Topics: Humans; Lactic Acid; Macrophages; Neoplasms; Tumor Microenvironment; Tumor-Associated Macrophages	2022
Lactic Acidosis in Patients with Solid Cancer. Antioxidants & redox signaling, 2022, Volume: 37, Issue:16-18 Topics: Acidosis, Lactic; Evidence Gaps; Humans; Lactic Acid; Neoplasms; Tumor Microenvironment	2022
Metabolic reservoir cycles in cancer. Seminars in cancer biology, 2022, Volume: 86, Issue:Pt 3 Topics: Glutamic Acid; Glutamine; Glycogen; Humans; Lactic Acid; Neoplasms; Triglycerides	2022
Tumor Microenvironment: Lactic Acid Promotes Tumor Development. Journal of immunology research, 2022, Volume: 2022 Topics: Glycolysis; Humans; Lactic Acid; Neoplasms; Neovascularization, Pathologic; Tumor Microenvironment	2022
Historical perspective of tumor glycolysis: A century with Otto Warburg. Seminars in cancer biology, 2022, Volume: 86, Issue:Pt 2 Topics: Glycolysis; Humans; Lactic Acid; Mitochondria; Neoplasms; Oxygen	2022
Understanding lactate sensing and signalling. Trends in endocrinology and metabolism: TEM, 2022, Volume: 33, Issue:10 Topics: Humans; Inflammation; Lactic Acid; Neoplasms; Signal Transduction	2022
Lactate metabolism in human health and disease. Signal transduction and targeted therapy, 2022, 09-01, Volume: 7, Issue:1 Topics: Glycolysis; Homeostasis; Humans; Inflammation; Lactic Acid; Neoplasms	2022
lncRNAs: Key Regulators of Signaling Pathways in Tumor Glycolysis. Disease markers, 2022, Volume: 2022 Topics: Glucose; Glycolysis; Humans; Lactic Acid; Neoplasms; Nucleotides; Oxygen; RNA, Long Noncoding; Signa	2022
Lactate-Lactylation Hands between Metabolic Reprogramming and Immunosuppression. International journal of molecular sciences, 2022, Oct-08, Volume: 23, Issue:19 Topics: Histones; Humans; Immunologic Deficiency Syndromes; Immunosuppression Therapy; Lactic Acid; Lysine;	2022
Lactic acid and lactate: revisiting the physiological roles in the tumor microenvironment. Trends in immunology, 2022, Volume: 43, Issue:12 Topics: Animals; CD8-Positive T-Lymphocytes; Humans; Lactic Acid; Mammals; Neoplasms; Tumor Microenvironment	2022
Targeting lactate-related cell cycle activities for cancer therapy. Seminars in cancer biology, 2022, Volume: 86, Issue:Pt 3 Topics: Animals; Cell Cycle; Citric Acid Cycle; Energy Metabolism; Humans; Lactic Acid; Neoplasms; Rats	2022
Lactate from the tumor microenvironment - A key obstacle in NK cell-based immunotherapies. Frontiers in immunology, 2022, Volume: 13 Topics: Humans; Immunotherapy; Killer Cells, Natural; Lactic Acid; Neoplasms; Tumor Microenvironment	2022
Tumor glycolysis, an essential sweet tooth of tumor cells. Seminars in cancer biology, 2022, Volume: 86, Issue:Pt 3 Topics: Citric Acid Cycle; Glucose; Glycolysis; Humans; Lactic Acid; Neoplasms	2022
Role of LDH in tumor glycolysis: Regulation of LDHA by small molecules for cancer therapeutics. Seminars in cancer biology, 2022, Volume: 87 Topics: Cell Line, Tumor; Cell Proliferation; Glycolysis; Humans; Isoenzymes; L-Lactate Dehydrogenase; Lacta	2022
Engineering lactate-modulating nanomedicines for cancer therapy. Chemical Society reviews, 2023, Feb-06, Volume: 52, Issue:3 Topics: Antineoplastic Agents; Drug Carriers; Humans; Lactic Acid; Nanomedicine; Neoplasms; Tumor Microenvir	2023
Lactate, histone lactylation and cancer hallmarks. Expert reviews in molecular medicine, 2023, 01-09, Volume: 25 Topics: Carcinogenesis; Epigenomics; Histones; Humans; Lactic Acid; Neoplasms	2023
Beyond metabolic waste: lysine lactylation and its potential roles in cancer progression and cell fate determination. Cellular oncology (Dordrecht), 2023, Volume: 46, Issue:3 Topics: Epigenesis, Genetic; Glycolysis; Humans; Lactic Acid; Lysine; Neoplasms	2023
Targeting monocarboxylate transporters (MCTs) in cancer: How close are we to the clinics? Seminars in cancer biology, 2023, Volume: 90 Topics: Glycolysis; Humans; Lactic Acid; Membrane Transport Proteins; Monocarboxylic Acid Transporters; Neop	2023
Tumor lactic acid: a potential target for cancer therapy. Archives of pharmacal research, 2023, Volume: 46, Issue:2 Topics: Energy Metabolism; Humans; Lactic Acid; Neoplasms; Signal Transduction	2023
The crosstalking of lactate-Histone lactylation and tumor. Proteomics. Clinical applications, 2023, Volume: 17, Issue:5 Topics: Epigenesis, Genetic; Glycolysis; Histones; Humans; Lactic Acid; Neoplasms; Tumor Microenvironment	2023
Lactylation: novel epigenetic regulatory and therapeutic opportunities. American journal of physiology. Endocrinology and metabolism, 2023, 04-01, Volume: 324, Issue:4 Topics: Epigenesis, Genetic; Epigenomics; Histones; Humans; Lactic Acid; Neoplasms	2023
Lactate-induced protein lactylation: A bridge between epigenetics and metabolic reprogramming in cancer. Cell proliferation, 2023, Volume: 56, Issue:10 Topics: Carcinogenesis; Cell Transformation, Neoplastic; Epigenesis, Genetic; Histones; Humans; Lactic Acid;	2023
The Warburg effect: a signature of mitochondrial overload. Trends in cell biology, 2023, Volume: 33, Issue:12 Topics: Glucose; Glycolysis; Humans; Lactic Acid; Mitochondria; Neoplasms	2023
Lactate in exhaled breath condensate and its correlation to cancer: challenges, promises and a call for data. Journal of breath research, 2023, 07-28, Volume: 17, Issue:4 Topics: Biomarkers; Breath Tests; Exhalation; Humans; Lactic Acid; Neoplasms; Reproducibility of Results; Vo	2023
Unveiling the veil of lactate in tumor-associated macrophages: a successful strategy for immunometabolic therapy. Frontiers in immunology, 2023, Volume: 14 Topics: Glycolysis; Humans; Lactic Acid; Macrophages; Neoplasms; Tumor Microenvironment; Tumor-Associated Ma	2023
Lactate acidosis and simultaneous recruitment of TGF-β leads to alter plasticity of hypoxic cancer cells in tumor microenvironment. Pharmacology & therapeutics, 2023, Volume: 250 Topics: Acidosis; Humans; Hypoxia; Lactic Acid; Neoplasms; Transforming Growth Factor beta; Tumor Microenvir	2023
Innate lymphoid cells and tumor-derived lactic acid: novel contenders in an enduring game. Frontiers in immunology, 2023, Volume: 14 Topics: Glycolysis; Humans; Immunity, Innate; Lactic Acid; Lymphocytes; Neoplasms; Tumor Microenvironment	2023
How protons pave the way to aggressive cancers. Nature reviews. Cancer, 2023, Volume: 23, Issue:12 Topics: Humans; Hydrogen-Ion Concentration; Lactic Acid; Neoplasms; Protons; Tumor Microenvironment	2023
Histone lactylation regulates cancer progression by reshaping the tumor microenvironment. Frontiers in immunology, 2023, Volume: 14 Topics: Cell Differentiation; Histones; Humans; Lactic Acid; Neoplasms; Tumor Microenvironment	2023
Monocarboxylate transporters in cancer. Molecular metabolism, 2020, Volume: 33 Topics: Animals; Citric Acid Cycle; Energy Metabolism; Glucose; Humans; Lactic Acid; Metabolic Networks and	2020
[Regulation of tumor cell glycometabolism and tumor therapy]. Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi, 2019, Aug-25, Volume: 36, Issue:4 Topics: Energy Metabolism; Glucose; Glycolysis; Humans; Lactic Acid; Neoplasms; Neoplastic Stem Cells	2019
Crucial players in glycolysis: Cancer progress. Gene, 2020, Feb-05, Volume: 726 Topics: Adenosine Triphosphate; Animals; Apoptosis; Disease Progression; Glucose; Glycolysis; Humans; Lactic	2020
The Metabolic Profile of Tumor and Virally Infected Cells Shapes Their Microenvironment Counteracting T Cell Immunity. Frontiers in immunology, 2019, Volume: 10 Topics: Animals; Cell Hypoxia; Extracellular Vesicles; Glycolysis; Humans; Immune Tolerance; Lactic Acid; Li	2019
Lactate/GPR81 signaling and proton motive force in cancer: Role in angiogenesis, immune escape, nutrition, and Warburg phenomenon. Pharmacology & therapeutics, 2020, Volume: 206 Topics: Animals; Cancer-Associated Fibroblasts; Humans; Lactic Acid; Membrane Transport Proteins; Neoplasms;	2020
Lactate: Fueling the fire starter. Wiley interdisciplinary reviews. Systems biology and medicine, 2020, Volume: 12, Issue:3 Topics: Glucose; Humans; Inflammation; Lactic Acid; Monocarboxylic Acid Transporters; Neoplasms; Signal Tran	2020
Tumor Microenvironment: A Metabolic Player that Shapes the Immune Response. International journal of molecular sciences, 2019, Dec-25, Volume: 21, Issue:1 Topics: Amino Acids; Glucose; Humans; Immunity; Lactic Acid; Lymphocytes; Neoplasms; Tumor Microenvironment	2019
Lactate and Lactate Transporters as Key Players in the Maintenance of the Warburg Effect. Advances in experimental medicine and biology, 2020, Volume: 1219 Topics: Glycolysis; Humans; Lactic Acid; Monocarboxylic Acid Transporters; Neoplasms; Tumor Microenvironment	2020
Lactic Acid: A Novel Signaling Molecule in Early Pregnancy? Frontiers in immunology, 2020, Volume: 11 Topics: Dendritic Cells; Female; Glycolysis; Humans; Lactic Acid; Macrophages; Monocarboxylic Acid Transport	2020
The Immune Consequences of Lactate in the Tumor Microenvironment. Advances in experimental medicine and biology, 2020, Volume: 1259 Topics: Cell Proliferation; Glycolysis; Humans; Lactic Acid; Neoplasms; Tumor Microenvironment	2020
Cancer Cell Metabolites: Updates on Current Tracing Methods. Chembiochem : a European journal of chemical biology, 2020, 12-11, Volume: 21, Issue:24 Topics: Amino Acids; Citric Acid; Glucose; Glycine; Humans; Isotope Labeling; Lactic Acid; Neoplasms; Succin	2020
Revisiting the Warburg Effect: Diet-Based Strategies for Cancer Prevention. BioMed research international, 2020, Volume: 2020 Topics: Animals; Caloric Restriction; Clinical Trials as Topic; Diet; Glycolysis; Humans; Lactic Acid; Neopl	2020
Revisiting lactate dynamics in cancer-a metabolic expertise or an alternative attempt to survive? Journal of molecular medicine (Berlin, Germany), 2020, Volume: 98, Issue:10 Topics: Animals; Cell Survival; Cell Transformation, Neoplastic; Energy Metabolism; Glycolysis; Humans; Lact	2020
Lactate modulation of immune responses in inflammatory versus tumour microenvironments. Nature reviews. Immunology, 2021, Volume: 21, Issue:3 Topics: Biological Availability; Carrier Proteins; Humans; Inflammation; L-Lactate Dehydrogenase; Lactic Aci	2021
Otto Warburg: The journey towards the seminal discovery of tumor cell bioenergetic reprogramming. Biochimica et biophysica acta. Molecular basis of disease, 2021, 01-01, Volume: 1867, Issue:1 Topics: Biochemistry; Cellular Reprogramming; Energy Metabolism; History, 20th Century; History, 21st Centur	2021
Oncometabolites lactate and succinate drive pro-angiogenic macrophage response in tumors. Biochimica et biophysica acta. Reviews on cancer, 2020, Volume: 1874, Issue:2 Topics: Angiogenesis Inhibitors; Cell Hypoxia; Cellular Reprogramming; Drug Resistance, Neoplasm; Humans; La	2020
Digging deeper through glucose metabolism and its regulators in cancer and metastasis. Life sciences, 2021, Jan-01, Volume: 264 Topics: Animals; Biomarkers, Tumor; Carbohydrate Metabolism; Glucose; Glycolysis; Humans; Lactic Acid; Neopl	2021
Lactic Acid and an Acidic Tumor Microenvironment suppress Anticancer Immunity. International journal of molecular sciences, 2020, Nov-07, Volume: 21, Issue:21 Topics: Humans; Hydrogen-Ion Concentration; Immunity; Immunosuppression Therapy; Immunosuppressive Agents; I	2020
Hypoxia Dictates Metabolic Rewiring of Tumors: Implications for Chemoresistance. Cells, 2020, 12-04, Volume: 9, Issue:12 Topics: Amino Acids; Animals; Citric Acid Cycle; Dimerization; Disease Progression; Drug Resistance, Neoplas	2020
The metabolism of cancer cells during metastasis. Nature reviews. Cancer, 2021, Volume: 21, Issue:3 Topics: Acetates; Adenosine Triphosphate; Animals; Cell Plasticity; Fatty Acids; Glutamine; Humans; Lactic A	2021
Postbiotics, Metabolic Signaling, and Cancer. Molecules (Basel, Switzerland), 2021, Mar-11, Volume: 26, Issue:6 Topics: beta-Glucans; Butyrates; Dietary Supplements; Fatty Acids, Volatile; Gastrointestinal Microbiome; Hu	2021
Lactic acid in macrophage polarization: The significant role in inflammation and cancer. International reviews of immunology, 2022, Volume: 41, Issue:1 Topics: Humans; Inflammation; Lactic Acid; Macrophage Activation; Macrophages; Neoplasms; Signal Transductio	2022
Lactate-Dependent Regulation of Immune Responses by Dendritic Cells and Macrophages. Frontiers in immunology, 2021, Volume: 12 Topics: Animals; Autoimmunity; Cell Cycle Proteins; Dendritic Cells; Humans; Immunomodulation; Infections; I	2021
Protein networks linking Warburg and reverse Warburg effects to cancer cell metabolism. BioFactors (Oxford, England), 2021, Volume: 47, Issue:5 Topics: Animals; Epithelial Cells; Glycolysis; Humans; Lactic Acid; Mice; Neoplasms; Warburg Effect, Oncolog	2021
EDIM-TKTL1/Apo10 Blood Test: An Innate Immune System Based Liquid Biopsy for the Early Detection, Characterization and Targeted Treatment of Cancer. International journal of molecular sciences, 2017, Apr-20, Volume: 18, Issue:4 Topics: Animals; Apoptosis; Biological Evolution; Biomarkers, Tumor; Biopsy; Blood Chemical Analysis; Early	2017
Lactic acid alleviates stress: good for female genital tract homeostasis, bad for protection against malignancy. Cell stress & chaperones, 2018, Volume: 23, Issue:3 Topics: Animals; Autophagy; Female; Genitalia, Female; Homeostasis; Humans; Lactic Acid; Neoplasms; Stress,	2018
The Glycogen Shunt Maintains Glycolytic Homeostasis and the Warburg Effect in Cancer. Trends in cancer, 2017, Volume: 3, Issue:11 Topics: Animals; Carrier Proteins; Glucose; Glycogen; Glycolysis; Homeostasis; Humans; Lactic Acid; Membrane	2017
Metabolic coupling and the Reverse Warburg Effect in cancer: Implications for novel biomarker and anticancer agent development. Seminars in oncology, 2017, Volume: 44, Issue:3 Topics: Adenosine Triphosphate; Antineoplastic Agents; Apoptosis Regulatory Proteins; Cell Proliferation; Dr	2017
Polymeric Immunonanoparticles Mediated Cancer Therapy: Versatile Nanocarriers for Cell-Specific Cargo Delivery. Critical reviews in therapeutic drug carrier systems, 2018, Volume: 35, Issue:1 Topics: Antibodies, Monoclonal; Antineoplastic Agents; Cancer Vaccines; Dendritic Cells; Drug Administration	2018
Including the mitochondrial metabolism of L-lactate in cancer metabolic reprogramming. Cellular and molecular life sciences : CMLS, 2018, Volume: 75, Issue:15 Topics: Adenosine Triphosphate; Cell Proliferation; Energy Metabolism; Glycolysis; Humans; Lactic Acid; Mito	2018
[In process]. Medizinische Monatsschrift fur Pharmazeuten, 2016, Volume: 39, Issue:10 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; B7-H1 Antigen; Blo	2016
Targeting cancer metabolism through synthetic lethality-based combinatorial treatment strategies. Current opinion in oncology, 2018, Volume: 30, Issue:5 Topics: Amino Acid Transport System ASC; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Ph	2018
Lactate transporters as therapeutic targets in cancer and inflammatory diseases. Expert opinion on therapeutic targets, 2018, Volume: 22, Issue:9 Topics: Animals; Biological Transport; Cell Membrane; Drug Design; Humans; Inflammation; Lactic Acid; Molecu	2018
Lactate as a signaling molecule: Journey from dead end product of glycolysis to tumor survival. Frontiers in bioscience (Landmark edition), 2019, 01-01, Volume: 24, Issue:2 Topics: Cell Hypoxia; Cell Line, Tumor; Cell Survival; Glycolysis; Humans; Hydrogen-Ion Concentration; Hypox	2019
Lactate: A Metabolic Driver in the Tumour Landscape. Trends in biochemical sciences, 2019, Volume: 44, Issue:2 Topics: Animals; Humans; Lactic Acid; Neoplasms	2019
Fuelling cancer cells. Nature reviews. Endocrinology, 2019, Volume: 15, Issue:2 Topics: Asparagine; Aspartic Acid; Disease Progression; Female; Humans; Lactic Acid; Male; Neoplasms; Oxygen	2019
The Warburg effect: essential part of metabolic reprogramming and central contributor to cancer progression. International journal of radiation biology, 2019, Volume: 95, Issue:7 Topics: Adenosine Triphosphate; Animals; Biomass; Cell Line, Tumor; Cell Proliferation; Cellular Reprogrammi	2019
Hypoxia/pseudohypoxia-mediated activation of hypoxia-inducible factor-1α in cancer. Cancer science, 2019, Volume: 110, Issue:5 Topics: Cell Hypoxia; Gene Expression Regulation, Neoplastic; Glycolysis; Humans; Hypoxia-Inducible Factor 1	2019
Sensing between reactions - how the metabolic microenvironment shapes immunity. Clinical and experimental immunology, 2019, Volume: 197, Issue:2 Topics: Bacteria; Fatty Acids, Volatile; Humans; Immunity, Innate; Immunologic Surveillance; Lactic Acid; Me	2019
Unappreciated Role of LDHA and LDHB to Control Apoptosis and Autophagy in Tumor Cells. International journal of molecular sciences, 2019, Apr-27, Volume: 20, Issue:9 Topics: Animals; Apoptosis; Autophagy; Cell Line, Tumor; Energy Metabolism; Humans; Isoenzymes; L-Lactate De	2019
Can Exercise-Induced Modulation of the Tumor Physiologic Microenvironment Improve Antitumor Immunity? Cancer research, 2019, 05-15, Volume: 79, Issue:10 Topics: Adaptive Immunity; Antibody Formation; Exercise; Glucose; Humans; Immunity, Innate; Lactic Acid; Neo	2019
The Tumor Metabolic Microenvironment: Lessons from Lactate. Cancer research, 2019, 07-01, Volume: 79, Issue:13 Topics: Glucose; Glycolysis; Humans; Lactic Acid; Monocarboxylic Acid Transporters; Neoplasms; Tumor Microen	2019
Synthesis and metabolism of methylglyoxal, S-D-lactoylglutathione and D-lactate in cancer and Alzheimer's disease. Exploring the crossroad of eternal youth and premature aging. Ageing research reviews, 2019, Volume: 53 Topics: Aging, Premature; Alzheimer Disease; Animals; Energy Metabolism; Glutathione; Glycolysis; Humans; La	2019
Cancer-generated lactic acid: a regulatory, immunosuppressive metabolite? The Journal of pathology, 2013, Volume: 230, Issue:4 Topics: Animals; Antineoplastic Agents; Cell Survival; Drug Design; Energy Metabolism; Glycolysis; Humans; H	2013
Hypoxia, lactate accumulation, and acidosis: siblings or accomplices driving tumor progression and resistance to therapy? Advances in experimental medicine and biology, 2013, Volume: 789 Topics: Acidosis; Disease Progression; Drug Resistance, Neoplasm; Humans; Hypoxia; Lactic Acid; Neoplasms	2013
Disrupting proton dynamics and energy metabolism for cancer therapy. Nature reviews. Cancer, 2013, Volume: 13, Issue:9 Topics: Autophagy; Bicarbonates; Carbonic Acid; Carbonic Anhydrases; Cation Transport Proteins; Energy Metab	2013
Targeting lactate metabolism for cancer therapeutics. The Journal of clinical investigation, 2013, Volume: 123, Issue:9 Topics: Animals; Antineoplastic Agents; Biological Transport; Homeostasis; Humans; L-Lactate Dehydrogenase;	2013
Targeting lactate metabolism for cancer therapeutics. The Journal of clinical investigation, 2013, Volume: 123, Issue:9 Topics: Animals; Antineoplastic Agents; Biological Transport; Homeostasis; Humans; L-Lactate Dehydrogenase;	2013
Targeting lactate metabolism for cancer therapeutics. The Journal of clinical investigation, 2013, Volume: 123, Issue:9 Topics: Animals; Antineoplastic Agents; Biological Transport; Homeostasis; Humans; L-Lactate Dehydrogenase;	2013
Targeting lactate metabolism for cancer therapeutics. The Journal of clinical investigation, 2013, Volume: 123, Issue:9 Topics: Animals; Antineoplastic Agents; Biological Transport; Homeostasis; Humans; L-Lactate Dehydrogenase;	2013
Carbonic anhydrase IX: regulation and role in cancer. Sub-cellular biochemistry, 2014, Volume: 75 Topics: Anaerobiosis; Antigens, Neoplasm; Carbon Dioxide; Carbonic Anhydrase IX; Carbonic Anhydrases; Cell H	2014
PLGA-based nanoparticles as cancer drug delivery systems. Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:2 Topics: Antineoplastic Agents; Drug Delivery Systems; Humans; Lactic Acid; Nanoparticles; Neoplasms; Polygly	2014
The Warburg effect in tumor progression: mitochondrial oxidative metabolism as an anti-metastasis mechanism. Cancer letters, 2015, Jan-28, Volume: 356, Issue:2 Pt A Topics: Anoikis; Cell Proliferation; Citric Acid Cycle; Glucose; Glycolysis; Humans; Hypoxia-Inducible Facto	2015
"In vitro" 3D models of tumor-immune system interaction. Advanced drug delivery reviews, 2014, Dec-15, Volume: 79-80 Topics: Animals; Cell Culture Techniques; Cell Differentiation; Cell Hypoxia; Cytokines; Disease Progression	2014
Analysis of hypoxia-induced metabolic reprogramming. Methods in enzymology, 2014, Volume: 542 Topics: Autophagy; Carbon Isotopes; Cell Culture Techniques; Culture Media; Glucose; Glycolysis; Humans; Hyd	2014
Comprehensive review on lactate metabolism in human health. Mitochondrion, 2014, Volume: 17 Topics: Alanine; Carbon Dioxide; Diabetes Mellitus; Glucose; Humans; Lactic Acid; Metabolic Networks and Pat	2014
Targeting cancer with nano-bullets: curcumin, EGCG, resveratrol and quercetin on flying carpets. Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:9 Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents; Antioxidants; Apoptosis; Catechin; Cell Pro	2014
The Warburg effect: molecular aspects and therapeutic possibilities. Molecular biology reports, 2015, Volume: 42, Issue:4 Topics: Antineoplastic Agents; Dichloroacetic Acid; Epigenesis, Genetic; Genes; Glycolysis; Humans; Lactic A	2015
ALPHA glycolytic vasculogenesis better correlates with MRI and CT imaging techniques than the traditional oxygen vasculogenesis theory. AJR. American journal of roentgenology, 2014, Volume: 203, Issue:6 Topics: Animals; Computer Simulation; Female; Glycolysis; Humans; Lactic Acid; Magnetic Resonance Imaging; M	2014
Lactate as an insidious metabolite due to the Warburg effect. Molecular biology reports, 2015, Volume: 42, Issue:4 Topics: Glycolysis; Humans; Lactic Acid; Neoplasms	2015
Introduction to the molecular basis of cancer metabolism and the Warburg effect. Molecular biology reports, 2015, Volume: 42, Issue:4 Topics: Apoptosis; Genes, Neoplasm; Glycolysis; Humans; Lactic Acid; Mitochondria; Neoplasms; Pyruvic Acid;	2015
Cancer metabolism and the Warburg effect: the role of HIF-1 and PI3K. Molecular biology reports, 2015, Volume: 42, Issue:4 Topics: Animals; Cell Proliferation; Glycolysis; Humans; Hypoxia-Inducible Factor 1; Lactic Acid; Mammals; N	2015
Hypoxia, cancer metabolism and the therapeutic benefit of targeting lactate/H(+) symporters. Journal of molecular medicine (Berlin, Germany), 2016, Volume: 94, Issue:2 Topics: Animals; Antineoplastic Agents; Basigin; Biomarkers; Energy Metabolism; Humans; Hypoxia; Lactic Acid	2016
Sirtuins and the Metabolic Hurdles in Cancer. Current biology : CB, 2015, Jun-29, Volume: 25, Issue:13 Topics: Biosynthetic Pathways; Cell Transformation, Neoplastic; Energy Metabolism; Gluconeogenesis; Humans;	2015
Particulate Systems Based on Poly(Lactic-co-Glycolic)Acid (pLGA) for Immunotherapy of Cancer. Current pharmaceutical design, 2015, Volume: 21, Issue:29 Topics: Animals; Antibodies; Cancer Vaccines; Drug Delivery Systems; Humans; Immunotherapy; Lactic Acid; Nan	2015
Lactic acid bacteria: reviewing the potential of a promising delivery live vector for biomedical purposes. Microbial cell factories, 2015, Sep-16, Volume: 14 Topics: Autoimmune Diseases; Drug Delivery Systems; Gastrointestinal Tract; Genetic Vectors; Gram-Positive B	2015
Metabolic changes associated with tumor metastasis, part 1: tumor pH, glycolysis and the pentose phosphate pathway. Cellular and molecular life sciences : CMLS, 2016, Volume: 73, Issue:7 Topics: Epithelial-Mesenchymal Transition; Glucose-6-Phosphate Isomerase; Glycolysis; Humans; Lactic Acid; N	2016
Na(+)/H(+) antiporter (NHE1) and lactate/H(+) symporters (MCTs) in pH homeostasis and cancer metabolism. Biochimica et biophysica acta, 2016, Volume: 1863, Issue:10 Topics: Biological Transport, Active; Cation Transport Proteins; Glycolysis; Homeostasis; Humans; Hydrogen;	2016
Mutant p53 proteins alter cancer cell secretome and tumour microenvironment: Involvement in cancer invasion and metastasis. Cancer letters, 2016, 07-01, Volume: 376, Issue:2 Topics: Animals; Cell Communication; Cell Movement; Cytokines; Extracellular Matrix; Genetic Predisposition	2016
Progress in research and application of PLGA embolic microspheres. Frontiers in bioscience (Landmark edition), 2016, 06-01, Volume: 21, Issue:5 Topics: Animals; Chemoembolization, Therapeutic; Embolization, Therapeutic; Humans; Lactic Acid; Microsphere	2016
Cancer metabolism: a therapeutic perspective. Nature reviews. Clinical oncology, 2017, Volume: 14, Issue:1 Topics: Acetyl Coenzyme A; Adaptation, Physiological; Amino Acids; Antineoplastic Agents; Antioxidants; Auto	2017
Lactobacillus crispatus as biomarker of the healthy vaginal tract. Annales de biologie clinique, 2016, Aug-01, Volume: 74, Issue:4 Topics: Biomarkers; Cytotoxicity, Immunologic; Female; Health; Humans; Lactic Acid; Lactobacillus crispatus;	2016
PLGA Nanoparticles and Their Versatile Role in Anticancer Drug Delivery. Critical reviews in therapeutic drug carrier systems, 2016, Volume: 33, Issue:2 Topics: Antineoplastic Agents; Chemistry, Pharmaceutical; Drug Carriers; Humans; Lactic Acid; Models, Chemic	2016
Lactate at the crossroads of metabolism, inflammation, and autoimmunity. European journal of immunology, 2017, Volume: 47, Issue:1 Topics: Animals; Arthritis, Rheumatoid; Autoimmune Diseases; Autoimmunity; Energy Metabolism; Humans; Immune	2017
The Warburg effect: 80 years on. Biochemical Society transactions, 2016, 10-15, Volume: 44, Issue:5 Topics: Adenosine Triphosphate; Energy Metabolism; Glucose; Glycolysis; Humans; Lactic Acid; Mitochondria; M	2016
Reexamining cancer metabolism: lactate production for carcinogenesis could be the purpose and explanation of the Warburg Effect. Carcinogenesis, 2017, 02-01, Volume: 38, Issue:2 Topics: Carcinogenesis; Glycolysis; Humans; Lactic Acid; Mitochondria; Neoplasms; Neovascularization, Pathol	2017
Lactate, a Neglected Factor for Diabetes and Cancer Interaction. Mediators of inflammation, 2016, Volume: 2016 Topics: Animals; Cell Line, Tumor; Diabetes Complications; Diabetes Mellitus; Disease Progression; Humans; H	2016
Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies. Cancer cell, 2017, 03-13, Volume: 31, Issue:3 Topics: Amino Acids; Cytotoxicity, Immunologic; Fatty Acids; Genes, p53; Glucose; Humans; Lactic Acid; Neopl	2017
Metabolic regulation by lactate. IUBMB life, 2008, Volume: 60, Issue:9 Topics: Blood Glucose; Diabetes Mellitus; Energy Metabolism; Exercise; Homeostasis; Humans; Insulin; Lactic	2008
Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. Pharmacology & therapeutics, 2009, Volume: 121, Issue:1 Topics: Amino Acid Transport Systems; Animals; Cation Transport Proteins; Cell Line, Tumor; Cell Proliferati	2009
Pyruvate into lactate and back: from the Warburg effect to symbiotic energy fuel exchange in cancer cells. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2009, Volume: 92, Issue:3 Topics: Cell Death; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Energy Metabolism; Glycolysis; Humans; La	2009
Tumor cell energy metabolism and its common features with yeast metabolism. Biochimica et biophysica acta, 2009, Volume: 1796, Issue:2 Topics: Animals; Apoptosis; Citric Acid Cycle; Energy Metabolism; Fermentation; Glucose; Glycolysis; Humans;	2009
The anti-oxidant capacity of tumour glycolysis. International journal of radiation biology, 2009, Volume: 85, Issue:11 Topics: Animals; Antioxidants; DNA Damage; Glycolysis; Humans; Hypoxia; Lactic Acid; Luminescent Measurement	2009
The altered metabolism of tumors: HIF-1 and its role in the Warburg effect. Advances in enzyme regulation, 2010, Volume: 50, Issue:1 Topics: Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Glucose; Glycolysis; Humans; Hypoxia-Induc	2010
Tumor metabolism of lactate: the influence and therapeutic potential for MCT and CD147 regulation. Future oncology (London, England), 2010, Volume: 6, Issue:1 Topics: Animals; Basigin; Humans; Lactic Acid; Monocarboxylic Acid Transporters; Neoplasms	2010
Waves of gene regulation suppress and then restore oxidative phosphorylation in cancer cells. The international journal of biochemistry & cell biology, 2011, Volume: 43, Issue:7 Topics: Adaptation, Biological; Cell Hypoxia; Cell Proliferation; Energy Metabolism; Gene Expression Regulat	2011
PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Advanced drug delivery reviews, 2011, Mar-18, Volume: 63, Issue:3 Topics: Animals; Antineoplastic Agents; Capillary Permeability; Drug Delivery Systems; Extravasation of Diag	2011
Suppression of T-cell responses by tumor metabolites. Cancer immunology, immunotherapy : CII, 2011, Volume: 60, Issue:3 Topics: Humans; Lactic Acid; Neoplasms; Signal Transduction; T-Lymphocytes, Cytotoxic; Tumor Microenvironmen	2011
Design of biocompatible dendrimers for cancer diagnosis and therapy: current status and future perspectives. Chemical Society reviews, 2011, Volume: 40, Issue:5 Topics: Biocompatible Materials; Contrast Media; Dendrimers; Drug Design; Humans; Lactic Acid; Neoplasms; Po	2011
[Encounter of cancer cells with bone. Development of cancer therapy targeted on acidic microenvironment and acidic organelle of cancer cells]. Clinical calcium, 2011, Volume: 21, Issue:3 Topics: Acridine Orange; Animals; Glycolysis; Humans; Lactic Acid; Lysosomes; Mice; Mitochondria; Neoplasms;	2011
Engineered PLGA nanoparticles: an emerging delivery tool in cancer therapeutics. Critical reviews in therapeutic drug carrier systems, 2011, Volume: 28, Issue:1 Topics: Animals; Antineoplastic Agents; Drug Carriers; Drug Delivery Systems; Gene Transfer Techniques; Gene	2011
Possibilities of poly(D,L-lactide-co-glycolide) in the formulation of nanomedicines against cancer. Current drug targets, 2011, Jul-01, Volume: 12, Issue:8 Topics: Antineoplastic Agents; Chemistry, Pharmaceutical; Colloids; Drug Administration Routes; Drug Compoun	2011
Advanced drug delivery systems of curcumin for cancer chemoprevention. Cancer prevention research (Philadelphia, Pa.), 2011, Volume: 4, Issue:8 Topics: Animals; Anticarcinogenic Agents; Chemoprevention; Curcumin; Drug Delivery Systems; Emulsions; Human	2011
Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations. Advanced drug delivery reviews, 2011, Sep-10, Volume: 63, Issue:10-11 Topics: Adjuvants, Immunologic; Animals; Cancer Vaccines; Dendritic Cells; Drug Delivery Systems; Humans; Im	2011
Enabling anticancer therapeutics by nanoparticle carriers: the delivery of Paclitaxel. International journal of molecular sciences, 2011, Volume: 12, Issue:7 Topics: Antineoplastic Agents, Phytogenic; Drug Carriers; Humans; Lactic Acid; Magnetite Nanoparticles; Meta	2011
Lactate shuttles at a glance: from physiological paradigms to anti-cancer treatments. Disease models & mechanisms, 2011, Volume: 4, Issue:6 Topics: Animals; Antineoplastic Agents; Biological Transport; Humans; L-Lactate Dehydrogenase; Lactic Acid;	2011
Lactate: a metabolic key player in cancer. Cancer research, 2011, Nov-15, Volume: 71, Issue:22 Topics: Animals; Cell Movement; Glycolysis; Humans; Lactic Acid; Neoplasms; Radiation Tolerance; Tumor Escap	2011
Biodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccines. Journal of nanobiotechnology, 2011, Nov-28, Volume: 9 Topics: Chitosan; Cyanoacrylates; Gelatin; Humans; Lactic Acid; Nanocapsules; Neoplasms; Particle Size; Phar	2011
Regulation of glycolytic and mitochondrial metabolism by ras. Current pharmaceutical biotechnology, 2013, Volume: 14, Issue:3 Topics: Animals; Epithelial Cells; Glycolysis; Humans; Lactic Acid; Mitochondria; NAD; Neoplasms; ras Protei	2013
Cell-specific siRNA delivery by peptides and antibodies. Methods in enzymology, 2012, Volume: 502 Topics: Antibodies; Cell Line, Tumor; Cross-Linking Reagents; Drug Carriers; Humans; Lactic Acid; Liposomes;	2012
PLGA-based nanoparticles: an overview of biomedical applications. Journal of controlled release : official journal of the Controlled Release Society, 2012, Jul-20, Volume: 161, Issue:2 Topics: Animals; Bacterial Infections; Brain Diseases; Cardiovascular Diseases; Drug Delivery Systems; Human	2012
Multiple biological activities of lactic acid in cancer: influences on tumor growth, angiogenesis and metastasis. Current pharmaceutical design, 2012, Volume: 18, Issue:10 Topics: Humans; Lactic Acid; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasms; Neovascularization, Path	2012
Role of monocarboxylate transporters in human cancers: state of the art. Journal of bioenergetics and biomembranes, 2012, Volume: 44, Issue:1 Topics: Amino Acid Sequence; Animals; Glycolysis; Humans; Hydrogen-Ion Concentration; Lactic Acid; Metabolic	2012
Tumor metabolism as modulator of immune response and tumor progression. Seminars in cancer biology, 2012, Volume: 22, Issue:4 Topics: Acidosis; Amino Acids; Animals; Biological Transport; Disease Progression; Glycolysis; Humans; Immun	2012
Anticancer agents that counteract tumor glycolysis. ChemMedChem, 2012, Volume: 7, Issue:8 Topics: Antineoplastic Agents; Drug Evaluation, Preclinical; Enzymes; Glycolysis; Humans; Hypoxia-Inducible	2012
Clinical importance of lactic acid bacteria: a short review. Acta bio-medica : Atenei Parmensis, 2011, Volume: 82, Issue:3 Topics: Cardiovascular Diseases; Diarrhea; Humans; Lactic Acid; Lactobacillus; Neoplasms; Probiotics	2011
Emerging roles of PKM2 in cell metabolism and cancer progression. Trends in endocrinology and metabolism: TEM, 2012, Volume: 23, Issue:11 Topics: Animals; Carrier Proteins; Cell Proliferation; Cell Transformation, Neoplastic; Disease Progression;	2012
Endothelial cell metabolism and implications for cancer therapy. British journal of cancer, 2012, Oct-09, Volume: 107, Issue:8 Topics: Endothelial Cells; Glucose; Glycolysis; Humans; Lactic Acid; Neoplasms; Neovascularization, Patholog	2012
[Tumor pathophysiology]. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2012, Volume: 188 Suppl 3 Topics: Animals; Blood Glucose; Cell Hypoxia; Energy Metabolism; Humans; Lactic Acid; Neoplasm Invasiveness;	2012
Cancer metabolism: what we can learn from proteomic analysis by mass spectrometry. Cancer genomics & proteomics, 2012, Volume: 9, Issue:6 Topics: Energy Metabolism; Glutamine; Glycolysis; Humans; L-Lactate Dehydrogenase; Lactic Acid; Lysosomes; M	2012
Endothelial cell metabolism and tumour angiogenesis: glucose and glutamine as essential fuels and lactate as the driving force. Journal of internal medicine, 2013, Volume: 273, Issue:2 Topics: Angiogenesis Inhibitors; Endothelial Cells; Endothelium, Vascular; Glucose; Glutamine; Glycolysis; H	2013
Nanomaterial-based functional scaffolds for amperometric sensing of bioanalytes. Analytical and bioanalytical chemistry, 2013, Volume: 405, Issue:11 Topics: Animals; Biosensing Techniques; Blood Glucose; Cholesterol; Electrochemical Techniques; Equipment De	2013
The importance of tumor metabolism in cancer prognosis and therapy; pre-clinical studies on rodent tumors with agents that improve tumor oxygenation. Advances in enzyme regulation, 2002, Volume: 42 Topics: Animals; Blood Glucose; Carbon Dioxide; Humans; Lactic Acid; Magnetic Resonance Imaging; Neoplasms;	2002
[Lactate . pyruvate]. Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60 Suppl 8 Topics: Acidosis, Lactic; Biomarkers; Diabetes Mellitus; Humans; Lactic Acid; Neoplasms; Pyruvic Acid	2002
Lactate: mirror and motor of tumor malignancy. Seminars in radiation oncology, 2004, Volume: 14, Issue:3 Topics: Cell Hypoxia; Cell Transformation, Neoplastic; Female; Humans; Hyaluronic Acid; Hypoxia-Inducible Fa	2004
Lactate in solid malignant tumors: potential basis of a metabolic classification in clinical oncology. Current medicinal chemistry, 2004, Volume: 11, Issue:16 Topics: Animals; Humans; Lactic Acid; Medical Oncology; Neoplasms	2004
PLGA microspheres for improved antigen delivery to dendritic cells as cellular vaccines. Advanced drug delivery reviews, 2005, Jan-10, Volume: 57, Issue:3 Topics: Animals; Antigen Presentation; Antigens; Dendritic Cells; Humans; Immunotherapy; Lactic Acid; Micros	2005
Cancer's molecular sweet tooth and the Warburg effect. Cancer research, 2006, Sep-15, Volume: 66, Issue:18 Topics: Aerobiosis; Animals; Glucose; Glycolysis; Humans; Hypoxia-Inducible Factor 1; Lactic Acid; Neoplasms	2006
Hypoxia signalling controls metabolic demand. Current opinion in cell biology, 2007, Volume: 19, Issue:2 Topics: Animals; Cell Hypoxia; Humans; Hydrogen-Ion Concentration; Hypoxia-Inducible Factor 1; Hypoxia-Induc	2007
Tumor-induced modulation of dendritic cell function. Cytokine & growth factor reviews, 2008, Volume: 19, Issue:1 Topics: Animals; Cell Differentiation; Cyclooxygenase 2; Dendritic Cells; Dinoprostone; Humans; Hypoxia; Lac	2008
Metabolic alterations and lactate overproduction in insulin-resistant states. Advances in experimental medicine and biology, 1994, Volume: 354 Topics: Animals; Glucose; Humans; Insulin Resistance; Lactates; Lactic Acid; Neoplasms; Obesity	1994
Nutritional and physiological consequences of tumour glycolysis. Parasitology, 1993, Volume: 107 Suppl Topics: Animals; Dietary Carbohydrates; Energy Metabolism; Gluconeogenesis; Glucose; Glycolysis; Humans; Lac	1993
Magnetic resonance spectroscopy and imaging methods for measuring tumour and tissue oxygenation. The British journal of cancer. Supplement, 1996, Volume: 27 Topics: Electron Spin Resonance Spectroscopy; Humans; Lactic Acid; Magnetic Resonance Imaging; Magnetic Reso	1996
Causes and consequences of tumour acidity and implications for treatment. Molecular medicine today, 2000, Volume: 6, Issue:1 Topics: Animals; Antineoplastic Agents; Extracellular Space; Glycolysis; Humans; Hydrogen-Ion Concentration;	2000
Microenvironmental influence on macrophage regulation of angiogenesis in wounds and malignant tumors. Journal of leukocyte biology, 2001, Volume: 70, Issue:4 Topics: Animals; Cell Hypoxia; Glucose; Growth Substances; Humans; Lactic Acid; Macrophages; Mice; Neoplasms	2001

Article	Year
A phase II study of an herbal decoction that includes Astragali radix for cancer-associated anorexia in patients with advanced cancer. Integrative cancer therapies, 2010, Volume: 9, Issue:1 Topics: Aged; Anorexia; Astragalus Plant; Body Weight; Cytokines; Disease Progression; Drugs, Chinese Herbal	2010
Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Dec-10, Volume: 28, Issue:35 Topics: Administration, Topical; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Double-Blind	2010
Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Dec-10, Volume: 28, Issue:35 Topics: Administration, Topical; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Double-Blind	2010
Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Dec-10, Volume: 28, Issue:35 Topics: Administration, Topical; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Double-Blind	2010
Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Dec-10, Volume: 28, Issue:35 Topics: Administration, Topical; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Double-Blind	2010
Continuous abdominal fascial closure: a randomized controlled trial of poly(L-lactide/glycolide). Gynecologic oncology, 2003, Volume: 90, Issue:2 Topics: Abdominal Wall; Adult; Aged; Aged, 80 and over; Female; Glycolates; Humans; Lactic Acid; Middle Aged	2003
Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood, 2007, May-01, Volume: 109, Issue:9 Topics: Biological Transport; Cell Cycle Proteins; Cell Proliferation; Dose-Response Relationship, Drug; Fem	2007
Experimental studies and preliminary clinical trial of vinorelbine-loaded polymeric bioresorbable implants for the local treatment of solid tumors. Cancer research, 1991, Oct-01, Volume: 51, Issue:19 Topics: Adult; Animals; Antineoplastic Agents; Delayed-Action Preparations; Dogs; Dose-Response Relationship	1991

Intervention	participants (Number)
	Grade 3+ Adverse Event	Grade 4+ Adverse Event
Placebo Cream	18	3
Urea/Lactic Acid Cream	21	3

lactic acid and Benign Neoplasms